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Abstract
Human parvovirus B19 is a minute ssDNA virus causing a wide variety of diseases,
including erythema infectiosum, arthropathy, anemias, and fetal death. After primary
infection, genomic DNA of B19 has been shown to persist in solid tissues of not only
symptomatic but also of constitutionally healthy, immunocompetent individuals. In this
thesis, the viral DNA was shown to persist as an apparently intact molecule of full length,
and without persistence-specific mutations. Thus, although the mere presence of B19
DNA in tissue can not be used as a diagnostic criterion, a possible role in the pathogenesis
of diseases e.g. through mRNA or protein production can not be excluded. The molecular
mechanism, the host-cell type and the possible clinical significance of B19 DNA tissue
persistence are yet to be elucidated.
In the beginning of this work, the B19 genomic sequence was considered highly
conserved. However, new variants were found: V9 was detected in 1998 in France, in
serum of a child with aplastic crisis. This variant differed from the prototypic B19
sequences by ~10 %. In 2002 we found, persisting in skin of constitutionally healthy
humans, DNA of another novel B19 variant, LaLi. Genetically this variant differed from
both the prototypic sequences and the variant V9 also by ~10%. Simultaneously, B19
isolates with DNA sequences similar to LaLi were introduced by two other groups, in the
USA and France. Based on phylogeny, a classification scheme based on three genotypes
(B19 types 1-3) was proposed.
Although the B19 virus is mainly transmitted via the respiratory route, blood and
plasma-derived products contaminated with high levels of B19 DNA have also been
shown to be infectious. The European Pharmacopoeia stipulates that, in Europe, from the
beginning of 2004, plasma pools for manufacture must contain less than 104 IU/ml of B19
DNA. Quantitative PCR screening is therefore a prerequisite for restriction of the B19
DNA  load  and  obtaining  of  safe  plasma  products.  Due  to  the  DNA  sequence  variation
among the three B19 genotypes, however, B19 PCR methods might fail to detect the new
variants. We therefore examined the suitability of the two commercially available
quantitative B19 PCR tests, LightCycler-Parvovirus B19 quantification kit (Roche
Diagnostics) and RealArt Parvo B19 LC PCR (Artus), for detection, quantification and
differentiation of the three B19 types known, including B19 types 2 and 3.  The former
method was highly sensitive for detection of the B19 prototype but was not suitable for
detection of types 2 and 3.  The latter method detected and differentiated all three B19
virus types. However, one of the two type-3 strains was detected at a lower sensitivity.
Then, we assessed the prevalence of the three B19 virus types among Finnish blood
donors, by screening pooled plasma samples derived from >140 000 blood-donor units:
none of the pools contained detectable levels of B19 virus types 2 or 3. According to the
results of other groups, B19 type 2 was absent also among Danish blood-donors, and
extremely rare among symptomatic European patients. B19 type 3 has been encountered
endemically in Ghana and (apparently) in Brazil, and sporadical cases have been detected
in France and the UK.
We next examined the biological characteristics of these virus types. The p6 promoter
regions  of  virus  types  1-3  were  cloned  in  front  of  a  reporter  gene,  the  constructs  were
transfected into different cell lines, and the promoter activities were measured. As a result,
we found that the activities of the three p6 promoters, although differing in sequence by
>20%, were of equal strength, and most active in B19-permissive cells. Furthermore, the
infectivity of the three B19 types was examined in two B19-permissive cell lines. RT-PCR
revealed synthesis of spliced B19 mRNAs, and immunofluorescence verified the
production of NS1 and VP proteins in the infected cells. These experiments suggested
similar host-cell tropism and showed that the three virus types are strains of the same
species, i.e. human parvovirus B19. Last but not least, the sera from subjects infected in
the past either with B19 type 1 or type 2 (as evidenced by tissue persistence of the
respective DNAs), revealed in VP1/2- and VP2-EIAs a 100 % cross-reactivity between
virus types 1 and 2. These results, together with similar studies by others, indicate that the
three B19 genotypes constitute a single serotype.
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A6 DNA isolate of B19 type 2
aa amino acid
AAV adeno-associated virus
AIDS aquired immunodeficiensy
syndrome
AMDV aleutian mink disease virus
Au B19 type 1 isolate
B19 human parvovirus B19
BFU-E erythroid burst-forming units
BM bone marrow
CP crossing point
bp base pair
BPV bovine parvovirus
CDS coding sequence
CFU-E erythroid colony forming units
CnMV canine minute virus
CPV canine parvovirus
D91.1 DNA isolate of B19 type 3
DNA  deoxyribonucleotide
EI erythema infectiosum
EIA enzyme immuno assay
ETS epitope-type specificity
(of antibodies)
FH fulminant hepatitis
FPV feline parvovirus
FRET fluorescence resonance
energy transfer
HA hemagglutination assay
HAA hepatitis-associated aplastic anemia
HaAM DNA isolate of B19 type 2
HBoV human bocavirus
HBV hepatitis B-virus
HCV hepatitis C-virus
HIV human immunodeficiency virus
HUVEC human umbilical vein endothelial
cells
IC internal control
ICTV International Committee on
Taxonomy of Viruses
ICTVdb the Universal Virus Database
of the ICTV
IF immunofluorescence
IgG immunoglobulin G
IgM immunoglobulin M
IM-81 B19 type 2-containing serum
ITR inverted terminal repeat
IVDU intravenous drug user
kb kilobase
kDa kilodalton
LaLi DNA isolate of B19 type 2
LC-PCR light-cycler PCR
mRNA messenger ribonucleic acid
MVM minute virus of mice
NAN B19 type 1-containing serum
NHLF normal human lung fibroblasts
nm nanometer
NS1 non-structural protein of B19
nt nucleotide
NTP nucleotide triphosphate
ORF open reading frame
p6 B19 promoter
PARV4 Parvovirus 4
PARV5 Parvovirus 5
PCR  polymerase chain reaction
pi post infection
PLA2 phospholipase 2
PPV porcine parvovirus
qPCR quantitative polymerace
chain reaction
RA rheumatoid arthritis
RT-PCR reverse-transcription PCR
S/D plasma solvent-detergent treated
plasma
SDS-PAGE sodium dodecylsulphate
polyacrylamide gel electrophoresis
SPR3 B19 type 1-containing plasma
SPV simian parvovirus
ssDNA single-stranded DNA
SV40 simian virus 40
Tm melting temperature
V9 DNA isolate of B19 type 3
VLP virus-like particle
VP viral protein
VP1 structural protein of B19
VP1/2 virus-like particle containing
VP1 and VP2
VP1u unique region of VP1 protein
VP2 structural protein of B19
Wi B19 type 1 isolate
Å Ångström
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Parvoviruses
Parvoviridae
Parvoviruses  are  among  the  smallest  DNA  viruses  able  to  infect  mammalian  cells:  the
family name originates from the Latin word parvum, meaning small. Parvoviruses are
ubiquitous among animal kingdom, infecting vertebrates as well as insects. The unique
feature among viruses belonging to the family Parvoviridae is that their genome is a linear
and single-stranded DNA molecule (Crawford et al., 1969; Rose et al., 1969; Tattersall,
2006). The genomic DNA molecule is usually 4-6 kb in size, and contains at both ends
palindromic sequences that can be folded into hairpin structures essential for viral DNA
replication. These terminal sequences can either be identical or different from each other
(Tattersall, 2006).
Parvoviruses are, in general, structurally very simple, consisting of the DNA genome
that is packed in a protein shell. Virions of all parvoviruses lack lipids, and thus are
resistant to inactivation by organic solvents. None of the viral proteins are known to be
glycosylated (Muzyczka and Berns. 2001; Tattersall, 2006). The three-dimensional
structures of the virions have been determined for several parvoviruses, such as canine
parvovirus (CPV) (Tsao et al., 1991), adeno-associated virus 2 (AAV2) (Xie et al., 2002),
minute virus of mice (MVM) (Agbandje-McKenna et al., 1998; Kontou et al., 2005),
feline panleukopenia virus (FPV) (Agbandje et al., 1993), porcine parvovirus (PPV)
(Simpson et al., 2002) and human parvovirus B19 (Agbandje et al., 1991; Agbandje et al.,
1994; Kaufmann et al., 2004). The capsid shell is icosahedral, non-enveloped and only ~
18-26 nm in diameter. It is composed of 60 capsid protein particles arranged with T=1
symmetry, usually the smallest of the VP proteins (VP1-4, depending on the virus species)
being  the  major  component.  The  viral  proteins  are  alternative  forms  of  the  same  gene
product, predominantly differing in the N-terminus, and are translated from alternatively
spliced mRNAs or result from posttranslational cleavage (Muzyczka and Berns. 2001;
Tattersall, 2006). The main structural motif is an eight-stranded anti-parallel ?-barrell,
which is a highly conserved structure among most viral capsid structures (Rossmann and
Johnson, 1989). The insertions between the strands of the ?-barrell form large loops on the
capsid surface, and differ between distinct parvovirus species (Muzyczka and Berns.
2001).
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Parvovirinae
The Parvoviridae family is further divided into two sub-families on the basis of host
range: those infecting vertebrates comprise the Parvovirinae subfamily, and those
infecting insects and other arthropods compose the Densovirinae subfamily  (ICTVdB  -
The Universal Virus Database, version 4.; Tattersall et al. 2005). Viruses of the former
family each infect a single type of vertebrate host. Members of the latter group are not
discussed further within this thesis.
The  genome  organisation  of  all  parvoviruses  is  similar,  and  of  all  members  of  the
Parvovirinae, monosense (Tattersall, 2006). The region between the terminal palindromes
contains two open reading frames: one half contains the ORF encoding the non-structural
proteins required for DNA replication, and the other half contains the ORF encoding the
structural proteins of the capsid (Astell et al., 1983; Ozawa et al., 1987; Srivastava et al.,
1983). In some parvoviruses, other minor ORFs have been detected. Some parvoviruses
preferentially encapsidate ssDNA of negative polarity (the strand that is complementary to
mRNA), e.g. MVM, (Crawford et al.,  1969),  while  others  may  encapsidate  ssDNA
molecules  of  either  polarities,  e.g.  AAV  (Berns  and  Adler,  1972;  Rose et al., 1969).
Depending on the virus, there might be one, two or three promoters for mRNA
transcription. Further, some parvoviruses are capable of autonomous replication, while
others depend on co-infection of a helper-virus. According to these structural and
biological properties, and subsequently supplemented by computer-based phylogenetic
analysis,  members  of  the Parvovirinae subfamily are further divided into five genera:
Parvovirus, Erythrovirus, Dependovirus, Amdovirus and Bocavirus (ICTVdB - The
Universal Virus Database, version 4.; Tattersall et al. 2005; Tattersall, 2006).
Parvovirus
The type species of the Parvovirus genus  is  the  minute  virus  of  mice  (MVM).  The
majority of the species within the Parvovirus genus encapsidate the negative-strand DNA
genome (except LuIII where both polarities are encapsidated in equimolar amounts)
(Bates et al., 1984; Muzyczka and Berns. 2001). The hairpin structures at both ends of the
genome are different from each other in sequence, length, and in predicted structure
(Astell et al., 1983). Transcription is initiated by two promoters, at map unit ~4 and ~40,
and terminated in one polyadenylation site located near the 5´end (Pintel et al., 1983).
Parvoviruses are autonomously replicating viruses that do not require aid from a
helper-virus. Because of the limited coding capacity, however, the major requirement is
that the host cell must undergo the S phase, in order to accomplish a productive parvovirus
infection. Therefore, the host-cell-range of parvoviruses is narrow.
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Dependovirus
The Dependoviruses encapsidate both negative- and positive-strand DNA in equivalent
amounts (Berns and Adler, 1972; Rose et al., 1969). The hairpin structures at both ends of
the genome are identical, each containing inverted terminal repeats of 145 nt, of which the
distal 125 nts form a palindromic sequence (Berns and Hauswirth. 1984; Lusby et al.,
1980). Transcription of dependoviruses appears to be initiated from three promoters
located at map units ~5, ~19 and ~40, and terminated in one polyadenylation site near the
5´end (Green and Roeder, 1980; Lusby and Berns, 1982).
The helper-virus dependent parvoviruses were originally grouped together to form the
Dependovirus genus. It has been shown that for efficient replication, these viruses need
simultaneous co-infection of another virus, usually adeno or herpes viruses. Indeed, the
dependoviruses were initially discovered as contaminants of purified adenovirus stocks,
and they were therefore named adeno-associated viruses (AAV) (Atchison et al., 1965).
Infection without helper virus has been shown to result in a persistent latent infection.
During  such  latent-phase  of  infection,  at  least  AAV2  has  been  shown  to  integrate  site-
specifically into the 13.4q-qter on the host’s chromosome 19 (Kotin et al., 1990; Kotin et
al., 1991; Kotin et al., 1992; Samulski et al., 1991). In some in vitro conditions (some
chemical carcinogens and UV irradiation), however, AAV has been shown to replicate
independently, without the aid of helperviruses (Yakobson et  al., 1987). For example,
helper-virus free AAV replication has been observed in raft cultures of epithelial cells
(Meyers et al., 2000). After phylogenetic analysis, the autonomously replicating goose and
duck parvoviruses are also placed within the dependovirus genus (ICTVdB - The
Universal Virus Database, version 4.).
Amdovirus and Bocavirus
By phylogenetic analysis, two new genera, Amdovirus and Bocavirus, within the
subfamily of Parvovirinae were recently created (ICTVdB - The Universal Virus
Database, version 4.). The Amdovirus genus contains only one species, the Aleutian mink
disease virus (AMDV), while the Bocavirus genus contains two species, bovine
parvovirus (BPV) and canine minute virus (CnMV) (hence the name bovine and canine).
All members are autonomously replicating viruses that were earlier classified in the
Parvovirus genus.
The AMDV genome is a negative strand DNA of 4.8 kb containing different
palindromic sequences at each end (Alexandersen et al., 1988; Bloom et al., 1980; Hahn et
al., 1983). The major distinguishing feature of AMDV is the VP1 N-terminus, which is
reasonably shorter than those of other parvoviruses, and, in contrast to that of most other
parvoviruses, lacks a phospholipase A2 enzymatic core (Tattersall et al. 2005).
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The genome of bocaviruses is slightly larger than that of AMDV, ~5.5 kb, and has
different sequences at the two genomic ends (Chen et al., 1986; Schwartz et al., 2002),
and, unlike any other parvoviruses, encodes a nuclear phosphoprotein NP1 with unknown
function(s) (Chen et al., 1986; Lederman et al., 1984; Schwartz et al., 2002; Tattersall et
al. 2005).
Erythrovirus
Human parvovirus B19 is the type species of erythrovirus genus. It was found in 1974 in
serum of an asymptomatic blood donor while screening for hepatitis B virus surface
antigen (Cossart et al., 1975). Electron microscopy revealed the presence of ~23 nm
particles resembling parvoviruses. The original sample was coded “number 19 in panel
B”, whereby the virus was subsequently named B19. Characterisation of the genome
showed that it was a single-stranded DNA of ~5.6 kb in length, and the complementary
strands were shown to be encapsidated in separate virions. After complete sequencing of
the genome, it was definitively established that it was a parvovirus, and B19 was officially
accepted as a member of the Parvoviridae by the International committee of Taxonomy of
Viruses (ITCV) in 1985 (Brown, 2006). However, the B19 genome contains some unique
features: the terminal repeats are identical and considerably longer than those of the other
parvoviruses (Deiss et al., 1990), and there is only a single promoter (Doerig et al., 1987)
but two transcription termination (polyadenylation) sites (Ozawa et al., 1987). Eventually,
phylogenetic analysis showed that B19 did not cluster either with species within the
Parvovirus or Dependovirus genera. Therefore a new genus was created and, because of
the  extreme  tropism  of  B19  for  the  erythroid  lineage,  it  was  named Erythrovirus
(Tattersall, 2006). At first, B19 was the sole member of the new genus, but subsequently,
related viruses were isolated in cynomolgus monkeys (simian parvovirus, SPV)
(O'Sullivan et al., 1994), in Manchurian chipmunks (chipmunk parvovirus) (Yoo et al.,
1999), and rhesus- and pig-tailed macaques (pig-tailed and macacue parvoviruses)  (Green
et al., 2000), and are now classified as erythroviruses (ICTVdB - The Universal Virus
Database, version 4.).
New human parvoviruses
For a long time B19 was considered the only human pathogen of its  family.  Recently,  a
new human parvovirus was found in respiratory tract samples. By sequencing this virus
was shown to be related to the species within the genus Bocavirus, and was thus named
human bocavirus (HBoV) (Allander et al., 2005). Subsequently HBoV has been shown to
be prevalent in respiratory tract samples of small children with severe lower respiratory
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tract disease in several laboratories around the world (Bastien et al., 2007; Kesebir et al.,
2006; Ma et al., 2006; Manning et al., 2006; Sloots et al., 2006), and occasionally also in
adults (Kupfer et al., 2006; Maggi et  al., 2007). The virus has been associated with a
variety of respiratory conditions, e.g. fever, cough, bronchiolitis, pneumonia and
wheezing, and thus seems to be another human pathogen among parvoviruses. However,
in many cases co-infections with other respiratory viruses have been observed,
complicating the determination of the role of HBoV in the pathogenicity in those subjects
(Mahy, 2006).
Another  new  virus  was  discovered  in  plasma  of  an  HIV  negative,  HBV  positive
intravenous drug user (IVDU) with fatigue, night sweats, pharyngitis, neck stiffness,
vomiting, diarrhea, arthralgia and confusions (Jones et al., 2005). The newly found virus
resembled parvoviruses by DNA sequence, and was named parvovirus 4 (PARV4).
Phylogenetic analysis indicated that PARV4 was not related closely to any of the
previously known parvovirus groups, but situated closest to the erythro- and
dependoviruses. Subsequently, PARV4 and a related variant PARV5 have been found in
pooled plasma used for the manufacture of plasma products (Fryer et al.,  2006).  In  a
recent study, PARV4 and PARV5 were detected in serum of HCV-positive IVDUs, but
not in non-IVDUs (Fryer et al., 2007). Although this might point to transmission via blood
or plasma, as has been shown for B19, little is known about the role of these viruses in
human disease.
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Table 1: Classification of the family Parvoviridae (ICTVdB - The Universal Virus
Database, version 4.; Tattersall et al. 2005).
Subfamily Genus Type species
Densovirinae Brevidensovirus Aedes aegypti densovirus
Densovirus Junonia coenia densovirus
Iteravirus Bombyx mori densovirus
Pefudensovirus Periplaneta fuliginosa densovirus
Parvovirinae Dependovirus Adeno-associated virus 1
Adeno-associated virus 2
Adeno-associated virus 3
Adeno-associated virus 4
Adeno-associated virus 5
Avian adeno-associated virus
Bovine adeno-associated virus
Goose parvovirus
Duck parvovirus
Erythrovirus Human parvovirus B19
(Strains: A6, Au, LaLi, V9, Wi)
Pig-tailed macaque parvovirus
Rhesus macaque parvovirus
Simian parvovirus
Parvovirus Feline panleukopenia virus/
       Canine parvovirus
H-1 virus
Kilham rat virus
Minute virus of mice
Porcine parvovirus
Amdovirus Aleutian mink disease virus
Bocavirus Bovine parvovirus
Canine minute virus
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Human parvovirus B19
Molecular biology
Virion
The  B19  virion  is  simple,  composed  of  only  two  proteins  and  a  linear,  single  stranded
DNA molecule. Unlike in most of the other autonomous parvoviruses, genomes of either
negative or positive sense are encapsidated in equal amounts (Summers et al., 1983). The
non-enveloped capsid is only ~22 nm in diameter, and has a molecular weight of ~5.6 x
106 da, of which ~80% consists of protein and ~20% of DNA. The buoyant density in a
cesium chloride gradient has been measured to be ~1.43 g/ml (Clewley, 1984). The simple
structure and the absence of a lipid envelope make B19 extremely difficult to inactivate:
the virus is stable at 56°C for 60 minutes, it is not susceptible to pH (stable within the pH
range 3-9), and resists lipid solvents. It can be inactivated by formalin, ?-propriolactone
and oxidizing agents (Muzyczka and Berns. 2001).
B19 particles are icosahedrons (20-sided) and made up of 60 copies of the capsid
proteins VP1 and VP2, arranged in T=1 symmetry. VP2 is the major capsid protein of 58
kDa, comprising approximately 96 % of the virion structure (Ozawa and Young, 1987).
VP1 is the minor capsid protein comprising about 4 % of the virion structure (~3 copies /
capsid). The structural distribution of VP1 in the mature B19 capsid is not known. Based
on its amino acid sequence, VP1 is identical with the major capsid component VP2,
except that it contains 227 additional aa at the aminoterminus (= the VP1 unique region,
VP1u). This unique region has been reported to be located, at least in part, outside the
mature virus capsid (Kawase et al., 1995; Rosenfeld et al., 1992). Recent results, however,
suggest that VP1u becomes exposed on the capsid surface only after receptor attachment
(Ros et al., 2006).
B19 can not be produced in continuous cell lines in high yields, and therefore the
structure of the native B19 capsid has been difficult to study. However, small amounts (in
Chinese hamster ovary cells) of capsid structures have been observed to self-assemble
from the viral protein components (VP2 alone or VP2 and VP1 together) in the absence of
the B19 genome (Kajigaya et al., 1989). Empty B19 capsids have been produced in high
yields in a baculovirus expression system (Brown et al., 1991; Kajigaya et al., 1991), and
the structure of the recombinant VP2 capsid has been determined by X-ray
crystallography, with a resolution of ~3.5 Å (Kaufmann et al., 2004). The VP2 capsid was
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shown to contain the common eight-stranded antiparallell ?-barrell motif, but to differ
from the other autonomous parvoviruses in surface topology.
Genome
The  B19  genome  of  one  isolate  (Wi),  was  first  characterized  in  1984  (Cotmore  and
Tattersall, 1984), and two years later, a second isolate (Au) was described (Shade et al.,
1986). The B19 genome was shown to be a linear single-stranded DNA molecule of 5596
nucleotides (nt). After succesful cloning of the genomic ends, they were shown to contain
identical inverted terminal repeats (ITR) of ~380 nt that are self-complementary and able
to form double-stranded hairpin loops, and consist mainly of GC-pairs (Astell and
Blundell, 1989; Deiss et al., 1990; Zhi et  al.,  2004).  The  distal  ~365 nt  of  the  ITRs are
imperfect palindromes, with a few base asymmetries, leading to two distinct
configurations of which one is the reverse-complement of the other, and which are
referred to as flip and flop. The few unpaired nucleotides form “bubbles” in the double
stranded hairpin structure. The size and the positions of these bubbles seem to be
conserved among different B19 isolates (Deiss et al., 1990; Zhi et al., 2004). The ITRs are
used as primers for the complementary strand synthesis during replication, and by
experiments with clones containing full-length or truncated forms of ITRs, it has been
shown that the hairpin structure is essential for B19 replication (Zhi et  al., 2004). For
adeno-associated virus 2 (AAV2), the ITRs, resembling those of the B19 virus, have also
been reported to be essential for encapsidation and integration into the hosts chromosome
(Wang et al., 1996).
Replication mechanism
B19 genome replication takes place in the host cell nucleus. Because of the small size and
restricted coding capacity of the genome, parvoviruses do not possess their own
replication machinery but rely completely on that of the host cell. The unique feature of
parvoviruses is the single stranded, linear DNA genome. Because DNA polymerases
synthesize only in 5´-to 3´- direction and need a basepaired primer, copying of the extreme
3´-end of a linear DNA molecule is not simple. Therefore parvoviruses use a mechanism
called “rolling-hairpin replication” (Cotmore and Tattersall, 2006). The replication
mechanism in those parvoviruses containing distinct ITRs at the two genomic ends (e.g.
MVM) is more complex than in those containing identical ITRs (e.g. AAV). Since the
B19 genome resembles that of AAV in that the terminal sequences are identical, B19
probably uses a genome replication mechanism similar to that of AAV (Fig. 1).
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AAV replication (Berns and Hauswirth, 1984) is initiated by using the 3´- terminal
hairpin as primer for complementary strand synthesis. Elongation begins at the 3´-OH
group of the folded hairpin structure. As a polymerase completes the synthesis of the
complementary strand, a duplex form of the parental strand is formed, which is covalently
linked at one end. Then, a single strand cut is created exactly opposite of the original 3´-
parental terminus. This nicking is performed by homodimers of the viral NS1 protein, and
occurs via a nucleolytic transesterification reaction that liberates a 3´-nucleotide to further
prime the polymerase. The hairpin structure is then melted, and the original 3´-end of the
parental strand now forms the 5´-end of the progeny strand. The parental strand is then
repaired, resulting in displacement and inversion of the original (parental) 3´-terminal
sequence.
18
Figure 1: Replication mechanism of AAV, modified from (Berns and Hauswirth, 1984). From
Soderlund (1996), with permission.
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Transcription
 In the B19 genome, open reading frames are present only on the negative polarity strand,
with arrangement common to all parvoviruses: the 3´ side of the genome encodes the non-
structural protein NS1 and the 5´ side encodes the two capsid proteins VP1 and VP2
(Cotmore et  al., 1986; Ozawa et al., 1987; Ozawa et al., 1988b). As with other
parvoviruses, the two structural proteins of B19, VP1 and VP2, are encoded by the same
reading frame so that the gene for VP2 is completely included in that of VP1 (Ozawa et
al., 1988b). The VP1 gene contains additional 681 nucleotides that encode the VP1 unique
region of 227 amino acids in the aminoterminus. The capsid protein transcripts are
produced by alternative splicing. Two additional genes for small non-structural proteins,
the 7.5 and 11 kDa proteins, are present in the center and at the 5´ end of the genome
(Cotmore et al., 1986; Luo and Astell, 1993; Ozawa et al., 1987; Ozawa et al., 1988b; St
Amand et al., 1991; St Amand and Astell, 1993).
The only active promoter, p6, is located at the 3´-palindrome at map unit 6 and thus
regulates the synthesis of all nine transcripts (Doerig et al., 1987). According to the Au
reference sequence, nucleotides 258-321 have been shown to be necessary for in vitro
transcriptional activity in HeLa cells (Blundell et al., 1987). In the same study, the
translational start site (ATG) was recognized at nucleotide 350-351, downstream from the
TATA-box. Although several TATA-elements are located in the middle of the genome, no
other active B19 promoters have been recognized (Brown, 2006; Liu et al., 1991a; Ozawa
et al., 1987; Shade et al., 1986).
 The p6 promoter strength has been shown to be regulated by cellular factors binding
to the upstream enhancer elements (Figure 2) (Blundell and Astell, 1989; Liu et al.,
1991b, Raab et al. 2001). Nucleotides 100-190 and 233-298 have been shown to be
particularly important for p6 activity (Gareus et al., 1998). Transcription regulation is a
highly complicated and not fully understood event, in which a number of cellular factors
have been shown to be involved: the two GC-rich elements tandemly present upstream of
the TATA-box have been shown to be important through binding of the cellular
transactivating factors Sp1 and Sp3 (Blundell and Astell, 1989; Raab et al., 2001). Three
strong binding sites for another transcriptional regulator, YY1 (Shimomura et al., 1993),
and a core motif for Ets family proteins have also been determined (Vassias et al., 1998).
More recently, Raab et al. demonstrated binding of the Oct-1 protein to an octamer motif
(Raab et al., 2001). They also observed interaction of Sp3 with one of these boxes, and
suggested that the ratio of bound Sp1 and Sp3 might be involved in the regulation of p6
activity.
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Figure 2. Binding sites for cellular factors on the B19 p6 promoter. From Raab et al. (2001), with
permission.
In addition to the cellular factors, the viral NS1 protein has been shown to take part in
regulation of the p6 promoter activity (Doerig et al., 1990). For NS1 transactivation,
nucleotides 100-160 and the two GC boxes adjacent to the TATA-box have been shown to
be essential (Gareus et al., 1998). NS1 has been suggested to bind to DNA directly, since
it has been shown that oligonucleotides containing nucleotides 126-162 could be
immunoprecipitated with anti-NS1 antibodies, as well as through cellular factors (Brown,
2006; Raab et al., 2002).
The p6 promoter activity was initially shown not to be restricted to B19 permissive
cells (Liu et al., 1991a). However, by transfection of expression vectors, carrying the p6
promoter and the upstream enhancer elements upstream of a reporter gene (luciferase of
Pothinus pyralis), into different cell lines, the p6 transcriptional activity was shown to be
higher in permissive cell lines than in cell lines non-permissive for B19 (Gareus et  al.,
1998).
All nine B19 transcripts (Figure 3.) contain a short 5´ leader sequence of ~60 bases
(Blundell et al., 1987; Doerig et al., 1990; Ozawa et al., 1987; St Amand et al., 1991),
corresponding to nucleotides 350-406 according to the Au-reference sequence (Shade et
al., 1986). The corresponding region has been shown to be important for transcriptional
activity (Gareus et al., 1998). All but one of the transcripts contain large introns (Ozawa et
al., 1987). The single non-spliced transcript encodes the non-structural protein (NS1), and
the other eight transcripts, produced by differential splicing events, encode the two
structural proteins VP1 and VP2, and the two smaller proteins of 7.5 kDa and the 11 kDa,
of incompletely known functions. Two separate polyadenylation sites are used, one in the
middle of the genome, (pA)p, for the NS1- and 7.5 kDa- transcripts, and another in the 5´
end for the transcripts encoding the structural and 11 kDa proteins. Polyadenylation at the
(pA)p site prevents the RNA polymerase from including the VP1/2 ORF in the transcript.
Therefore, polyadenylation at this site must be incomplete: indeed, polyadenylation at the
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(pA)p uses a non-consensus cleavage and polyadenylation specificity factor-binding
hexanucleotide AUUAAA, to allow for efficient readthrough of p6-generated pre-mRNAS
into the VP1/2 coding region. Both upstream and downstream cis-acting elements and an
adjacent AAUAAC motif are involved in controlling the relative expression rates of the
non-structural and structural genes, which has been suggested to play a role in B19
tropism (Liu et al., 1992; Yoto et al., 2006). In cells non-permissive for B19 replication,
NS1 transcripts have been shown to predominate, while in B19 permissive cells the capsid
transcripts predominate (Leruez et al., 1994). Blocking of NS1 protein production in a
B19 permissive cell line UT-7 has been shown to abolish capsid protein mRNA
transcription (Shimomura et al., 1993).
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Figure 3: Transcription map for human parvovirus B19. From Brown (2006), reproduced by
permission of Edward Arnold (Publishers) Ltd.
Proteins
Structural proteins: The  two  structural  proteins  of  B19  are  VP1  (84  kDa)  and  VP2  (58
kDa). VP2 is the major capsid component, and mediates receptor binding (Brown et  al.,
1993). In the infected cells both capsid proteins are localized in the cytoplasm and also in
the nucleus, where it was suggested to be transported by aid of a non-conventional nuclear
localization signal at the carboxyl sequence of VP2 (Pillet et al., 2003). Both VP1 and
VP2 have been shown to contain epitopes for neutralizing antibodies (Kajigaya et al.,
1991; Sato et al., 1991). The unique region of VP1 contains a conserved secreted
phospholipase A2, which has been identified in several members of the Parvoviridae
(Zadori et al., 2001). The PLA2 motifs have been shown to be functional in B19 (Dorsch
et al., 2002) and other parvoviruses (Zadori et  al., 2001), and are probably required for
escape from late endosomes during viral trafficking to the nucleus after receptor mediated
entry (Suikkanen et al., 2003; Zadori et al., 2001).
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Non-structural protein NS1: The major non-structural protein of B19 virus, NS1, is of 671
aa  in  size  and  with  a  molecular  weight  of  77  kDa.  NS1  has  multiple  functions.  As
described, it acts as a transcription transactivator both by binding to the p6 promoter DNA
directly as well as via cellular transcription factors (Raab et al., 2002). The motifs
associated with single-strand nicking activities (Ding et al., 2002), and the region
containing the predicted ATPase / helicase domains and nucleoside triphosphate binding
(NTP) domains (Moffatt et al., 1998; Momoeda et  al., 1994b) are relatively conserved
among parvoviruses and are assumed to function during viral replication.
NS1 is located in the nucleus of the infected cell, (Ozawa and Young, 1987), and has
been shown to be cytotoxic and to block cellular proliferation (Ozawa et  al., 1988a;
Srivastava et al., 1990). By mutation analysis, the NTP-binding domain of NS1 has been
shown to be important for cytotoxicity (Moffatt et al., 1998; Momoeda et  al., 1994b),
which in erythroid lineage cells and liver-derived cells is likely accomplished via
induction of apoptosis (Moffatt et al., 1998; Poole et al., 2004; Poole et al., 2006; Sol et
al., 1999).
Small proteins: In addition to the two main open reading frames (ORF) encoding the non-
structural and capsid proteins, the B19 genome contains additional small ORFs, on the far
right side of the genome, and in the middle (Ozawa et al., 1987). Two of these ORFs (in
the middle and on the right) contain an in-frame ATG codon, and produce small proteins
of 7.5 and 11 kDa (Luo and Astell, 1993; St Amand et al.,  1991; St  Amand and Astell,
1993). Although the exact roles of these proteins are yet not known, in studies using an
infectious B19 clone, the 11 kDa protein participated in regulating the relative production
rate of the B19 capsid proteins (Zhi et al., 2006). However, the third potential small ORF,
in the middle of the genome, has not been shown to produce protein (Brown, 2006).
Cell tropism
The B19 virus shows extreme tropism for the erythrocyte precursors CFU-E and BFU-E in
bone marrow (Ozawa et al., 1986; Srivastava and Lu, 1988), but has also been found in
fetal myocardium and liver (Naides and Weiner, 1989). B19 can be cultured in primary
erythroid progenitor cells derived from bone marrow (Ozawa et  al., 1986), fetal liver
(Brown et al., 1991; Yaegashi et al., 1989) and umbilical cord blood (Sosa et al., 1992;
Srivastava et al., 1992). B19 has been propagated also in a few cell lines such as the
human megakaryocytic leukemia cell line MB-02 (Munshi et  al., 1993), the human
erythroblastoid cell line UT7/Epo (Shimomura et al., 1992), and the erythroid leukemia
cell lines KU812Ep6 (Miyagawa et al., 1999) and  JK-1 (Takahashi et al., 1993), although
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the yields of progeny viruses in these cell lines are low. In addition, low-level replication
has recently been reported also in a non-erythroid cell line U932 (Munakata et al., 2006).
Several features are associated with the B19 host-cell range (supporting productive
infection), such as the cellular receptor, the blood-group P antigen (Brown et al., 1993)
and co-receptors Ku80 (Munakata et al., 2005) and ???1 integrin (Weigel-Kelley et al.,
2003), intracellular transcription factors (Gareus et al., 1998; Raab et al., 2001; Vassias et
al., 1998), and the relative production rate of the structural and non-structural proteins in
the infected cells (Liu et al., 1992). The levels of protein types are possibly regulated via
atypical mRNA splicing (Brunstein et al., 2000), impared ribosome loading of structural
gene transcripts (Liu et al., 1992; Pallier et al., 1997), polyadenylation sites (Yoto et al.,
2006), or the 11-kDa protein function (Zhi et al., 2006).
Receptor and co-receptors
The receptor for B19 is the blood group P antigen or globoside (globotetraosylceramide
GalNAc(?1-3)Gal(?1-4)Gal(?1-4)GlcCer) (Brown et al., 1993). As other autonomously
replicating parvoviruses, B19 agglutinates red cells of primate origin. As
hemagglutination was observed also by using baculovirus-produced recombinant VP2
capsids, it was suggested to be mediated by the viral VP2 protein (Brown and Cohen,
1992). Hemagglutination, as well as infectivity of B19 virus in a hematopoietic colony
assay, was inhibited by purified globoside (Brown et al., 1993; Kaufmann et al., 2005). In
later studies, however, no binding of membrane-associated globoside to B19 capsids were
observed (Kaufmann et al., 2005).
The erythrocytes of subjects of the rare blood group p phenotype lack the P antigen
(frequency ~1 in 200 000). In infection studies, bone marrow cells from patients of p
phenotype were resistant to B19 infection (Brown et al., 1994), and the P antigen was thus
regarded as the cellular receptor for B19 virus. Globoside has been shown to be expressed
on erythrocytes, platelets, granulocytes, the lung, fetal heart, synovium, liver, kidney,
endothelium, and vascular smooth muscle (Cooling et al., 1995).
 It has been suggested that P antigen by itself might not be sufficient for succesful
infection by B19 virus, because i) mature red cells abundantly express P antigen on their
surface, but lack nuclei, a prerequisite for B19 replication and ii) a number of nonerythroid
cells express P antigen, yet are nonpermissive for B19 infection. Indeed, subsequent
studies have shown that the expression level of P antigen does not correlate with B19
binding, and suggest that the P antigen is necessary for binding but not sufficient for entry
of the virus into cells (Weigel-Kelley et al., 2001).
With a recombinant B19 vector (Ponnazhagan et al., 1998), cell-surface binding was
detected in all cell types expressing globoside on the plasma membrane, which also in this
25
study  was  not  sufficient  for  B19  entry.  Expression  of  marker  genes  carried  by  the  B19
vector, indicating viral entry and nuclear transport of the recombinant genome, could be
seen in two cell lines of epitheloid origin, 293 and HeLa, and also in two human primary
cell lines (human umbilical vein endothelial cells, HUVEC, and normal human lung
fibroblasts, NHLF), but not in the human erythroleukemia cell lines HEL and K562,
despite globoside on their surface. Subsequently, B19 entry was shown to be mediated by
???1-integrins in their high-affinity conformation (Weigel-Kelley et al., 2003), regulated
in a cell-type specific manner (Weigel-Kelley et al., 2006). Recently, expression of Ku80
on transfected HeLa cells was shown to enhance entry of B19, suggesting that Ku80
mediates efficient B19 entry in cooperation with globoside and probably with ???1-
integrins (Munakata et al., 2005).
Clinical aspects
Transmission
The B19 virus has been detected in respiratory secretions of viremic patients, and the
major route for B19-virus transmission is generally thought to be via aerosol droplets and
contaminated surfaces. In one study, B19 was administered intranasally into voluntary
healthy adults, who subsequently became viremic and seroconverted (Anderson et  al.,
1985). During pregnancy, the virus can be transmitted from the infected mother to the
fetus (Brown et al., 1984). The B19 receptor is abundant in the human placenta in early
gestation, which might provide a pathway for the virus (Jordan and DeLoia, 1999).
Transmission also occurs via blood or plasma products of various kinds (Siegl and
Cassinotti, 1998). High seroconversion rates and some cases of symptomatic illness have
been due to blood products prepared from B19-containing plasma pools, and rarely by
single-donor blood components (Cohen et al., 1997; Jordan et al., 1998; Mortimer et al.,
1983; Yee et  al., 1995; Zanella et al., 1995). As a non-enveloped virus with small
genomic size, B19 is resistant to ordinary physicochemical factors, including the solvent /
detergent (S/D) and heat treatments. Because of its minute size, the pathogen is also
relatively difficult to remove by filtration (Siegl and Cassinotti, 1998), although it is, at
least in part, removable using small pore size filters (Parkkinen et al., 2006; Terpstra et al.,
2006).
The plasma pools used for manufacture, in addition to B19 DNA, also contain
antibodies. However, in S/D plasma safety studies (Brown et al., 2001), the recipients
were shown to seroconvert due to pools containing B19 DNA in high titers (107 IU/ml).
They also became B19-DNA positive, verifying virus transmission. By contrast,
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transfusion of B19 DNA in concentrations below 104 IU/ml is not considered to result in
detectable seroconversion, with some exceptions (Blumel et al., 2002). Consequently,
according to the revised European Pharmacopoeia (2004), plasma pools used for human
anti-D immunoglobulin production, must not (after January 1st 2004) contain more than
104 IU/ml of B19 DNA. In order to identify such high-titer units, a quantitative DNA
detection method is required.
Disease associations
B19 infection is common worldwide. As documented by B19 specific immunoglobulin G
(IgG) antibodies in serum, 5-15 % of young children, 60 % of adults, and 85 % of the
geriatric population have been infected with this virus (Anderson et al., 1986; Cohen and
Buckley, 1988). Seasonal variation is seen, B19 infection occurring mainly during late
winter or early spring (Bremner and Cohen, 1994; Enders et al., 2007; Heegaard and
Brown, 2002). Although the B19 virus is connected with a wide spectrum of disease, large
proportion of infections remains subclinical, both in children and in adults (Heegaard and
Brown, 2002). In some cases symptoms are nonspecific and indistinguishable from
common  cold,  and  some  of  the  clinical  manifestations  are  mild  and  self-limited.  In
patients with shortened red cell survival, in the immunocompromised, or in pregnant
women, however, the infection may be severe. Variation in host genes has been shown to
be related with B19 associated symptoms (Kerr, 2005).
Erythema infectiosum: In 1983, B19 was shown to be the cause of the childhood rash
erythema infectiosum (EI), also called “slapped cheak” or fifth disease (Anderson et al.,
1984). The connection was later confirmed by experimentally infecting volunteers with
the virus (Anderson et al., 1985). In the immunocompetent host, EI is the most common
manifestation of B19 infection, and usually appears after viremia (approximately 18 days
after infection), simultaneously with appearance of B19 specific IgG antibodies (Heegaard
and Brown, 2002). EI is characterized by transient or recurrent rash typically beginning on
cheeks, and subsequently spreading to the trunk and limbs. Fluctuations of intensity may
be caused by environmental factors such as exposure to sunlight or heat, or physical
activity (Naides, 1993). B19 induced rash may be difficult to distinguish clinically from
that caused by other viruses. Usually EI is transient and requires no treatment.
Anemia: B19 is erythrotropic and infects the red cell precursors in bone marrow. In
subjects with shortened red cell survival, the infection may lead to aplastic crisis (Pattison
et al., 1981). In healthy subjects this condition is transient, but in the
immunocompromised (e.g. subjects with HIV infection, congenital immunodeficience, or
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those receiving immunosuppressive therapy) the anemia may become chronic (Kurtzman
et al., 1989; Kurtzman et al., 1987; Kurtzman et al., 1988).
Arthritis and arthralgia: The association between B19 infection and acute arthralgia or
arthritis was established in 1985 (Reid et al., 1985; White et al., 1985). In children with EI
the incidence of arthralgia is ~10 % or less, while in adults, arthralgia and arthritis are the
most common manifestations, affecting 60 % of women and 30 % of men (Heegaard and
Brown, 2002). The onset of joint symptoms coincides with the appearance of B19 specific
antibodies, and is therefore presumably immunologically mediated. Arthritis is often
symmetrical affecting preferentially the small joints of hands, wrists and knees (Reid et
al., 1985; White et al., 1985). In some cases arthropathy may become chronic, and even
fulfill the criteria of rheumatoid arthritis (RA) (Naides et al., 1990; White et al., 1985).
RA is a chronic, systemic inflammatory connective tissue disorder of unknown causative
mechanisms, and no specific diagnostic tests are available. The American College of
Rheumatology criteria for classification of rheumatoid arthritis are used to diagnose and
classify this disease (Smith and Arnett, 1991).
B19 infection and pregnancy: About 40 % of women of child bearing age do not have B19
specific antibodies, and are thus at risk of acute B19 infection and subsequent
transmission of the virus to the fetus. In case of maternal infection, diverse estimations
have  been  reported  on  the  rate  of  vertical  transmission.  Fetal  infection  may  be
asymptomatic, but has also been associated with fetal anemia, spontaneous abortion,
hydrops and death (Brown et al., 1984; Enders et al., 2006). Fetal death with or without
hydrops have been observed when maternal infection occurs in early gestation, in
approximately 11 % among those infected within the first 22 weeks (Enders et al., 2004;
Miller et al., 1998), but in some reports also later in pregnancy (Norbeck et al., 2002).
Most fetal complications (hydrops and death) occur within 12 weeks following maternal
B19 infection (Enders et al., 2004; Enders et al., 2006; Miller et al., 1998; Yaegashi,
2000).
Others: Other proposed disease associations include myocarditis and dilated
cardiomyopathy (Bultmann et al., 2003; Enders et al., 1998; Heegaard et al., 1998; Kuhl
et al., 2005a; Kuhl et al., 2005b), pneumonia (Beske et al., 2007; Janner et al., 1994),
nephritis (Diaz and Collazos, 2000; Nakazawa et al., 2000), hepatitis and fulminant liver
failure (Hillingso et  al., 1998; Karetnyi et al., 1999; Langnas et al., 1995; Yoto et  al.,
1996), neurological disorders including meningoencephalitis, cerebellar ataxia, seizure
and stroke (Barah et al., 2001; Barah et al., 2003), and several auto-immune-like diseases
such as the gloves and socks syndrome, Hashimoto´s thyroiditis, Wegener´s
granulomatosis and lupus-like syndromes (Lehmann et al., 2003; Nikkari et al., 1994).
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Treatment
No specific antiviral drug is available against B19 infection. Usually in the
immunocompetent host, treatment is not required, but patients with arthralgia may
sometimes be treated with anti-inflammatory drugs. In immunodeficient patients or in
subjects with increased turnover of red blood cells, chronic anemia or transient aplastic
crisis may be treated with erythrocyte transfusions and intravenous immunoglobulin
(IVIG) containing neutralizing antibodies. However, even after IVIG treatment viral
clearance is not always complete. Also in the case of fetal hydrops and / or anemia,
intrauterine erythrocyte transfusions have been shown to reduce the mortality rate
substantially (Broliden et al., 2006; Frickhofen et al., 1990; Hedman et al. 2006; Heegaard
and Brown, 2002; Kurtzman et al., 1989).
Diagnosis
Due to its extreme cell tropism, B19 virus is difficult to culture in continuous cell lines
and thus there are in general no virus isolation methods to be used in diagnostics.
Morphological markers (no / low level of mature erythroid precursors, presence of giant
pronormoblasts) in BM aspirates or peripheral blood are suggestive for acute B19
infection, but alone are not sufficient for diagnosis (Heegaard and Brown, 2002).
Numerous methods have been published for direct detection of B19 virus components:
B19 virus in serum can be detected by EM and hemagglutination (Brown and Cohen,
1992; Cossart et al., 1975; Curry et al., 2006); antigens can be detected with monoclonal
antibodies by EIA or immunoblot (Manaresi et al., 1999; Schwarz et al., 1988); viral
nucleic acid in serum can be detected by direct hybridization e.g. in dot blot format, which
is sensitive enough to detect acutely infected subjects with high viral loads, or by PCR,
which is far more sensitive and can therefore detect also low-level viremias (Clewley,
1989; Koch and Adler, 1990; Koch et  al., 1990). Serological methods are available for
detection of antibodies specific for B19 (Broliden et  al., 2006; Cohen et al., 1983;
Corcoran and Doyle, 2004; Enders et al., 2006; Kaikkonen et al., 1999; Soderlund et al.,
1995a; Soderlund et al., 1995b; Soderlund et al., 1997a).
Modern diagnostics of B19 infection is usually based on measurement of B19 IgG and
IgM antibodies in blood, and / or detection of B19 DNA by PCR (Broliden et al., 2006).
Acute B19 infection is usually diagnosed by the presence of B19-specific immunoglobulin
M. Experimental B19 infection of healthy adult volunteers showed, during 5-12 days after
exposure, transient viremia, which declined rapidly with the appearance of specific IgM
antibodies during the second week after inoculation (Anderson et al., 1985). IgM starts to
decline during the second month of clinical onset, but may persist for several months
(Anderson et al., 1986; Anderson et al., 1985; Hedman et al. 2006). IgG appears by the
29
end  of  the  third  week.  IgG  specific  for  VP1  and  for  conformational  epitopes  of  VP2
persist for life, while IgG recognizing linear epitopes of VP2 are expressed only during the
acute phase of B19 infection (Kaikkonen et al., 1999; Soderlund et al., 1995b; Soderlund.
1996). In addition, measurement of IgG avidity and epitope-type specificity can be used
for identifying primary infection (Enders et al., 2006; Kaikkonen et al., 1999; Kaikkonen
et al., 2001; Soderlund et al., 1995a; Soderlund et al., 1995b).
In diagnosis of the immunocompromized, PCR is often preferential (or
complementary)  to  serology.  Positive  PCR findings  in  blood  or  BM may  indicate  acute
infection. However, detectable levels of B19 DNA have been shown to remain in BM and
serum for extended time periods, even in healthy immunocompetent individuals (see
below). Quantitative PCR might be of use in distinguishing acute from remote infections;
however this issue is under ongoing study (de Haan et al., 2007; Enders et  al., 2006;
Enders et al., 2007).
B19 DNA in blood and bone marrow
In immunosuppressed individuals unable to produce neutralizing antibodies, B19 persists
in blood or in bone marrow (BM), with or without anemia (Kurtzman et al., 1987;
Kurtzman et al., 1988; LaMonte et al., 2004). B19 DNA has also been shown to persist in
BM of immunocompetent patients with recurrent or chronic arthropathies (Foto et  al.,
1993; Sasaki et al., 1995) and, to a lesser extent, in healthy subjects (Cassinotti et al.,
1997; Heegaard and Brown, 2002). Indeed, recently, Lundqvist et al. found among 50
rheumatic subjects, B19 DNA in 0% of blood but in 26% of BM samples (Lundqvist et
al., 2005), in contrast to a prevalence in BM of up to 9 % among healthy B19 seropositive
individuals as reported earlier (Cassinotti et al., 1997; Heegaard and Brown, 2002) and of
4% among seropositive patients with hematological disorders (Lundqvist et al., 1999).
However, this difference might be due to different detections methods, since the patients
and healthy controls were not studied in parallel within the same study (Lundqvist et al.,
2005).
However, even in the immunocompetent subjects’ blood, viral clearance is often
slower than previously believed (Musiani et al., 1995). Lindblom et al. assessed, more
recently, the kinetics of viral clearance after acute B19 infection in 5 immunocompetent
subjects with typical symptoms. By quantitative PCR, a rapid decrease in the viral load
was observed coincidentally with development of IgG antibodies and resolution of clinical
symptoms. However, the DNA levels remained detectable in 4/5 subjects through the 128-
week follow-up period (Lindblom et  al., 2005). Similarly, in studies among pregnant
women, Enders et al. observed a drastic decrease in viral loads during the first two weeks
of infection (Enders et al., 2006). The DNA levels did not differ between symptomatic and
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asymptomatic patients, and the symptoms were mainly self-limited despite persistence of
B19 DNAemia. In one patient, however, who maintained arthropathy for 1.5 years,
elevated DNA levels (~105 geq/ml) in serum were seen for >322 days. In this study, B19
DNA was detected for ?5 months in 20/22 patients (Enders et  al., 2006). By qualitative
and quantitative real-time PCRs, Candotti et al. (Candotti et al., 2004) detected a low-
level persistence of B19 DNA in blood of ~1 % of immunocompetent and
nonsymptomatic blood donors, despite the presence of B19-specific IgG antibodies.
Similar figures have been reported for pregnant women (Lefrere et al.,  2005).   In
multitransfused (immunocompetent) individuals, the B19-DNA prevalence can be higher
and persist, together with B19-IgG antibodies, for up to 5 years (Lefrere et al., 2005).
B19 DNA in tissue
Because B19 often causes transient and sometimes chronic arthropathy, it has been
considered a potential etiologic agent for rheumatoid arthritis. B19 DNA has been
detected in several studies in the synovial membranes and synovial fluid of patients with
arthritis (Cassinotti et al., 1998; Dijkmans et al., 1988; Franssila and Hedman, 2006; Kerr
et al., 1995; Nikkari et al., 1995; Pallier et al., 1997; Saal et al., 1992; Soderlund-
Venermo et al., 2002; Zakrzewska et al., 2001).
In studies by Söderlund et al., B19 DNA was detected by nested PCR, in the synovia
of constitutionally healthy, immunocompetent young adults with joint trauma, and with
serological evidence of pre-existing immunity (Soderlund et al., 1997b). This finding
showed  that  mere  detection  of  B19  DNA  in  the  synovial  tissue  can  not  be  used  as  a
diagnostic marker of chronic arthritis, although it did not exclude the possibility of B19
playing a role in the pathology of these diseases, e.g. through mRNA and protein
production.
Also other disease associations of B19 have been sought by detection of viral DNA in
corresponding tissues. B19 DNA and capsid proteins were detected in skin of a patient
with EI (Schwarz et al., 1994), and the presence of viral components therein was
concluded to suggest a direct role of B19 virus in the formation of the exanthematous rash
in erythema infection. Later B19 DNA was detected also in skin biopsies derived from
subjects with chronic urticaria (Vuorinen et al., 2002). In the latter study, as a control
group, skin biopsies from healthy adults were studied in parallel for B19 DNA. The results
showed that also a large proportion of healthy controls carried B19 DNA in skin. This
work thus verified the phenomenon observed by Söderlund et al. (Soderlund et al., 1997b)
and expanded it by suggesting that B19 DNA persistence is not restricted to synovial
tissue. Subsequently, in addition to skin and synovium, persistence of the B19 genome has
been detected in various tissue types, e.g. muscle, testis, liver, tonsils, brain, salivary gland
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and heart, (Baskan et al., 2007; Chevrel et al., 2000; De Stefano et al., 2003; Diss et al.,
1999; Eis-Hubinger et  al., 2001; Gray et al., 1998; Hobbs, 2006; Lotze et al., 2004;
Manning et al., 2007; Norja et al., 2006). The B19 genomes persisting in synovial tissue
and skin are characterized further in this thesis (I and II).
Sequence variation
At the onset of our studies, the B19 DNA sequence was considered extremely stable with
a variation of only ~1-2 %. The near-full-length nucleotide sequence was available from
only two blood-derived isolates Wi (Blundell et al., 1987), from an asymptomatic donor in
England, and Au (Shade et al., 1986), from a child with aplastic crisis in the USA.
A number of studies focused on finding the possible correlation between sequence
variations within the B19 genome with different outcomes of infection. In investigations
using restriction site polymorphism (RSP) (Mori et al., 1987; Morinet et al., 1986; Umene
and Nunoue, 1990; Umene and Nunoue, 1991), B19 isolates were assorted into several
genome types according to the restriction pattern. Partial sequences of the VP1/2 genes i)
from sequential isolates from an infected individual or ii) from a single community
outbreak or iii) from within the same household were essentially identical (Erdman et al.,
1996), while isolates from distinct epidemiological settings showed slightly higher
variation. Although some geographical clustering could be seen, genetic differences were
minor, and no disease associations were detected.
Comparison of sequences from serum samples of patients with acute or persistent B19
infection  revealed a higher degree of variation in patients with persistent infection than in
those with acute infection, both at DNA and amino acid level (Hemauer et al., 1996). This,
in one individual, was suggested to be due to continuous replication. Most variation was
located within the VP1 unique region and, however, remained ? 4 %. Because important
neutralizing epitopes are localized within this region, other studies focused on this area,
with similar results (Haseyama et al., 1998). Expressed VP1u-proteins with this kind of
low-level variation showed similar affinity for human monoclonal antibodies, also
comparable with recombinant VP1/2 capsids produced in a baculovirus system (Dorsch et
al., 2001).
In 1998, a new B19 variant was found in France, in blood from a child with severe
anemia (Nguyen et al., 1998; Nguyen et al., 1999). By sequencing, this new variant, V9,
differed by more than 10 % from the earlier recognized B19 isolates, demonstrating that
the B19 sequences could be much more divergent than previously thought.
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Aims of this study
i) to assess whether B19 DNA persists in human tissues as an intact molecule
or as fragmented
ii) to determine whether the synovium or skin-derived B19 viruses are
prototypic, or (persistence related?) variants
iii) to examine the suitability of the two (commercially available) real-time PCR
tests for detection, quantification and differentiation of all known B19 virus
types.
iv) to assess the prevalence of B19 virus types among Finnish blood donors.
v) to compare the biological and immunological characteristics of the newly
found virus types
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Materials and methods
Characterization of B19 DNA persisting in synovial tissue and
skin (I & II)
The first aim of this study was to characterize B19 DNA persisting in human synovial
tissue (I) and skin (II).
Samples
Synovial tissue: Samples of synovial tissue were obtained during arthroscopy from 30
constitutionally healthy adults (age span 18-53 years, mean 21) with joint trauma or
exertion (I).
Skin: Biopsies of skin were obtained from 34 subjects; 20 had inflammatory B19-
nonrelated dermatological lesions (Group 1) and 14 were healthy members of hospital
staff (Group 2). The range of birth year of these subjects was 1913-1991 (mean 1957).
Sera: Sera were obtained from all tissue donors for antibody testing. B19-IgG antibodies
were  measured  (I)  by  a  commercial  EIA (Dako,  Glostrup,  Denmark)  or  (II)  by  in-house
EIAs, and B19-IgM antibodies by the EIA of Biotrin (Dublin, Ireland). For further
evidence of the time of B19 primary infection, the sera of subjects examined in depth for
persisting B19 DNA were studied for epitope-type-specificity (ETS) of VP2-IgG
(Soderlund et al., 1995b) as described recently (Kaikkonen et al., 1999).
DNA extraction
DNA was purified by proteinase K digestion (0.45% NP-40, 0.45% Tween, 2.5 mM
MgCl2, 50 mM KCl, 1% gelatine in 10 mM Tris, pH 8.3) over night at 55°C followed by
10  min  at  95°C  to  inactivate  the  enzyme  (group  1  skin  samples),  or  by  proteinase  K
digestion followed by phenol/chloroform extraction and ethanol precipitation (synovial
tissue samples and group 2 skin samples).
PCRs
All the synovial tissue and skin samples were first screened for B19 DNA with a nested
PCR (VP1-PCR) amplifying a 1066 bp region in the middle of the genome. This method
is described in Soderlund et al. (1997b). Of all positive samples, the persisting B19 DNA
was further characterized with two additional nested PCRs, NS1- and VP2-PCR,
amplifying the NS1 gene and the VP2 gene, respectively. All the three PCRs (primer
sequences are shown in Table 2) and the corresponding hybridization probes were
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designed according to the sequence of the Au isolate (Shade et al., 1986). The second
round products of all three PCRs were detected by agarose gel electrophoresis and
ethidium bromide staining. In addition, the products were transferred to a nylon membrane
and hybridized with a digoxigenin-labelled probe specific for the corresponding genomic
region. Optimal reaction conditions for each primer set were determined using the control
DNA, extracted from the viremic serum NAN, as template.
Semi-quantification
To assess whether B19 DNA persists as an intact molecule or is fragmented, we examined,
by semi-quantification, whether or not all three genomic regions could be detected in
equal amounts. The sensitivities of the NS1 and VP2-PCR methods were equalized to the
level  of  the  VP1  PCR,  which  was  shown  to  detect  one  target  molecule  /  reaction
(Soderlund et al., 1997b). The detection sensitivities of all three PCRs were within one
logarithmic unit. For semi-quantification of the different B19 genomic regions, DNA
suspensions were diluted serially in 10-fold steps, and each dilution was studied by the
nested VP1-PCR. The last dilution giving a positive signal by ethidium bromide staining
(in this thesis referred to as end point titer) was then used as a template in the NS1- and
VP2-PCRs.
Duplex-PCR
To support our theory for the genomic intactness, of synovial DNA preparations diluted to
end point, both the VP2 and NS protein-coding sequences were amplified simultaneously
in  one  tube  (I).  The  first  PCR round  utilized  the  outer  primer  pairs  of  the  VP2  and  NS
reactions. The product was purified with High Pure PCR Product Purification Kit
(Boehringer Mannheim, Mannheim, Germany) and transferred to the second reaction tube.
Primers  for  the  nested  reaction  were  NSifwd,  NSirev,  rt1  and  VP2irev  (table  2).  The
resulting amplicons were 439 and 639 nucleotides in size, respectively, and they were
separated electrophoretically on a 1 % TAE-agarose gel and were Southern blotted.
Hybridization was done simultaneously with NS1 and VP2 probes.
Sequencing and phylogenetic analysis
Synovial  isolates (I): In order to assess whether the synovial B19 is of a unique genotype
or involves persistence-specific mutations that could be causally related to tissue tropism,
the protein-coding region (constituting ~97 % of the whole B19 genome) was amplified
and sequenced. These experiments were first conducted with synovial tissue of four
individuals (I); two subjects represented acute-phase infection and two subjects
represented long-term carriership. B19 DNA purified from these samples was amplified to
five partly overlapping amplicons of ~1000 bp, which together covered the whole protein
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coding region of the genome (I). Sequencing was done at the Institute of Biotechnology,
University  of  Helsinki.  The  sequences  of  B19  DNA  isolated  from  synovia  recently  or
remotely after infection were compared with each other and with blood-derived B19
sequences from GenBank. Phylogenetic analyses were performed of the four synovial
tissue-derived B19 sequences together with others from GenBank by using a 346-nt region
corresponding to viral nt. 2246 through 2789. Sequence alignments were done by using
CLUSTAL W version 1.75, and subsequent analyses were done by using the PHYLIP
package (Thompson et al., 1994).
Dermal isolates (II): While determining the molecular characteristics of the skin-derived
B19 DNA (II), we observed that most of the amplicons from the NS1- and VP2-PCRs did
not hybridize or hybridized only weakly. These amplicons were therefore (partly)
sequenced from several samples, either directly or after cloning (TA-cloning, Novagen
Inc., Darmstadt, Germany). In addition to the three B19 primer sets (VP1, NS1 and VP2
PCRs), others (Table 2), prepared according to the blood-derived reference sequence Au
or the current dermal B19 DNA, were used for amplification and sequencing to gain a near
full-length sequence from one dermal isolate, LaLi. This was from a subject representing
long-term carriership according to serological data. DNA sequences were obtained with
ABI  PRISM  (Perkin-Elmer,  Foster  City,  CA)  at  the  sequencing  core  facility  of  the
Haartman Institute, University of Helsinki, Finland. Again, sequences of the new variant,
LaLi, were compared with the prototypic dermal and synovial sequences, as well with
others found in GenBank. A phylogenetic analysis was performed by using the full-length
protein-coding sequence of the dermal isolate LaLi together with 13 B19 sequences from
GenBank (including 4 B19 DNA isolates persisting in synovial membranes and a Simian
parvovirus sequence).
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Table 2. Sequence data for primers used in this study.
PCR test Primer Sequence
VP1 PCR p6 GGAGAATCATTTGTCGGAAG
p3 CTTCTGCAGAATTAACTGAAGTC
p8 TGTGCTTACCTGTCTGGATTG
p5 AGG CTT GTG TAA GTC TTC AC
p1 ATGAGTAAAGAAAGTGGCAAATGG
NS1 PCR NSofwd ATGGAGCTATTTAGAGGGGTG
NSorev TTTGCAATCCAGACAGGTAAGC
NSifwd ACTGGTTGTGTGAAAACAGAGTG
NSirev TTTTCCTGCTACATCATTAAATGG
NSpfwd AGAGGATAAGTGGAAACTAGTTG
NSprev TACTGGAACACTTTTAGCAATGG
VP2 PCR VP2ofwd TGACTTCAGTTAATTCTGCAGAAG
VP2orev TGG GTG CAC ACG GCT TTT GG
VP2ifwd CTAGAATATCCTTACGCCCTGG
VP2irev GTGGCTGATGCAAACCCCATC
VP2pfwd CCATTTCTCATGGTCAGACCAC
VP2prev CCATACAGAACCCACCATTAGG
Sequencing rt1 AATTTAGAGGGCTGCAGTCAAC
NSs fwd GCAATGGCCATTGCTAAAAGTG
p9 CTTTAGGTATAGCCAACTGG
rts rev ATGTGTCAGGAACCCCTAAGC
K71 PCR          ofwd TTTACTGAAGACAAATGGAAGT
orev CACTGGGACAGTTTTGGCAATA
ifwd AGTGGATTTCAATCAATATACA
irev TCATAATTTTGGCATAATAATAG
VP1/2 cloning KK1 CTCAGAAAACGGGATCCCGATGACTTCAGTTAATTCTG
KK2 CGGGATCCCGTTACAATGGGTGCACACGGCT
KK3 GTGAAGATCTTCATGAGTAAAGAAAGTGGTAAATG
KK4 GGAATTCCTTACAATGGGTGCACACGGCTTT
Promoter cloning NheIfwd TTTGCTAGCTAGTTGCACGTCAACCCC
B19RNArev TGCATAAGGCGGGAAAAAGCCC
Prom5fwd TGTCCGCCATCTTGAACCG
Xhorev TTTCTCGAGGTTAGTAAGTTAAAAGTTAGTATAAATACCTGTTAG
XhoD91.1rev TTTCTCGAGGTTAGTAAGTTAAAAGTTAGTATAAATACCTGTTAG
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Detection methods for prototypic and variant B19 (II & III)
Qualitative PCRs
While VP1-PCR was able to detect (in addition to the prototypic B19 DNA) LaLi-like
B19 DNA, results of NS1- and VP2-PCRs on genotype 2-containing samples were
contradictory. Therefore, to identify genotype 2 strains from the VP1-positive samples,
primers specific for genotype 2 DNA were designed according to the sequence of the LaLi
DNA-isolate, AY044266 (II). To gain absolute specificity, this new PCR (K71-PCR) was
conducted in a nested format. After 2x40 cycles and electrophoresis, the PCR products
were detected by ethidium-bromide staining.
Quantitative PCRs
We compared the performances of two LightCycler-based qPCR assays for B19-DNA:
qPCR-1 (Parvovirus B19 Quantification Kit by Roche), and qPCR-2 (RealArtTM Parvo
B19  LC  PCR  by  Artus)  (III).  The  principle  in  both  assays  is  basically  the  same.  Each
provides B19-specific primers and two hybridization probes labelled with fluorescent
molecules. Hybridization leads to fluorescence resonance energy transfer (FRET) between
the two fluorophores, and the emitted light is measured by the LightCycler instrument.
Real-time (during amplification) monitoring of fluorescence intensities, relative to
external standards of known target concentrations, allows for quantification of the
accumulating product. To monitor the efficiencies of the nucleic acid extraction and the
PCR process, internal controls (IC) are amplified with the same primers as the target, but
hybridized with probes carrying different fluorophores.
The raw data created by either qPCR test were analyzed with LightCycler Software
version 3.5 (Roche). Crossing points and calculated concentrations were obtained by the
second derivative maximum method together with proportional base-line adjustment. This
method  calculates  the  fractional  cycle  number  of  the  Crossing  Point  (CP)  value  of  each
sample automatically and thus makes the method independent of user-born influences. A
previously generated color compensation file (Roche) was activated during the
LightCycler run to reduce flow-through signal from other channels.
Evaluation of the sensitivities of the two qPCRs for B19 genotypes 1-3
Primer sequences for both qPCR-1 and qPCR-2 assays were considered confidential by
the manufacturers. Therefore, we needed to map the approximate target regions for each
PCR assay in order to select, among plasmids containing parts of genotype 2, those
containing the appropriate target sequence (Figure 4, Table 3). For this purpose, the
amplicons of B19 genotype 1 produced by qPCR-1 and qPCR-2 were analyzed on
agaroses gel, transferred to a nylon membrane and hybridized with probes specific for two
different genomic regions, a 359-bp fragment of the NS1 gene (used for hybridizing
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products of the NS1-PCR) and a 354-bp fragment of the VP1 gene (used for hybridzing
the products of the VP1-PCR). Hybridization of the qPCR-1 amplicon gave a positive
result with the NS probe and a negative result with the VP1 probe. As the amplicon size of
qPCR-1 is ~170-180 bp and the overlapping area (covered by the NS probe) of the inserts
in plasmids pLaLi1 and pLaLi2 is 223 nucleotides, both of these plasmids probably
contain the target sequence of qPCR-1, and can be used as genotype 2 template in qPCR-
1. For evaluation, we chose pLaLi2, and to be sure, joined the three areas together by
cloning (plasmid pLaLi6). Southern hybridization of the qPCR-2 amplicon gave a positive
result with the VP1 probe and a negative result with the NS probe. As the VP1 probe
covers the VP1 unique region included in plasmid pLaLi3, this plasmid was chosen to be
used as a genotype-2 template sequence in qPCR-2.
The plasmid constructs carrying B19-virus DNA of the different genotypes were used
for evaluation of the two qPCR methods. DNA concentration of the genotype 1-containing
plasmid, pB19-Lit, was first measured by the validated (Hokynar et al, unpublished data)
qPCR-1 test. The DNA concentrations of all plasmids were then measured
spectrophotometrically and converted into plasmid copy numbers / ?l. The plasmid
preparations were equalized to contain 109 copies / ?l each. To confirm the concentrations,
serial dilutions of the equalized plasmid purifications were dot-blotted onto a nylon
membrane and hybridized with a digoxigenin-labelled probe against the plasmid
backbone.
In order to determine the sensitivity of the two B19 qPCR tests, qPCR-1 and qPCR-2,
ten-fold dilutions were used of the plasmid constructs that contained the DNA inserts from
each of the three genotypes. With both qPCRs, each dilution was tested in 1 to 3
replicates. The PCR reactions were performed as recommended by the manufacturer. In
every PCR run, water was included as a negative control. The WHO International
Standard for Parvovirus B19 DNA nucleic acid assays (NIBSC 99/800) (Saldanha et al.,
2002) was used as a positive control. Plasmids Litmus29, pSTBlue-1 and pcDNA2.1
without insert were studied for background by the plasmid backbone.
Differentiation of the B19 genotypes by melting curve analysis
The ability of qPCR-1 and qPCR-2 to differentiate the amplicons obtained from DNA of
different B19 genotypes was examined by melting curve analysis (segment 1: 95 °C, hold
time 15 s, slope 20°C/s, acquisition mode none. Segment 2: 40°C, hold time 15 s, slope 20
°C/s, acquisition mode none. Segment 3: 80 °C, hold time 0 s, slope 0.1 °C/s, acquisition
mode continuous). Melting points were determined with serial dilutions of DNA from
each genotype alone, as well as of mixtures of DNA of two or three genotypes in equal
amounts.
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Quantitative PCR of B19 DNA in clinical samples
To further examine the suitability of the PCR kits for identification of the three genotypes
under natural conditions, clinical samples previously shown to contain genotypes 1 (4 skin
biopsies) (II), 2 (6 skin biopsies) (II) or 3 (2 serum samples) (Nguyen et al., 1999; Servant
et al., 2002) were analyzed. DNA was purified by phenol-chloroform extraction followed
by ethanol precipitation. N.B., as pointed out by the manufacturer, phenol-based extraction
is not recommended for qPCR-2. Therefore, to detect possible DNA polymerase inhibitors
in these preparations, internal control (IC) provided in each kit was added to the master
mix  (0.5  ?l  /  reaction)  and  detected  on  channel  F3.  Two  dilutions  of  each  sample  were
studied in 1 to 4 replicates.
1 4935
NS1-probe VP1-probe
VP1-u VP2
pLaLi 2
pLaLi 3
pLaLi 6
pLaLi 1
NS1
Figure 4. Schematic illustration of the positions (on the LaLi-sequence) of the NS1- and VP1-
probes, and the inserts of plasmids pLaLi1, pLaLi2, pLaLi3 and pLaLi6, used for qPCR
evaluation.
40
Table 3. Plasmid constructs used in qPCR evaluation.
*) Plasmids pV9-C22 and pD91.1-C10 were kindly donated by A. Garbarg-Chenon. Empty plasmid (with no
insert) pSTBlue-1, Litmus29 and pcDNA2.1 were used as negative controls.
Prevalence of variant B19 (II & III)
Plasma pools: All blood donations collected at the Finnish Red Cross Blood Transfusion
Service since January 2002 have been pre-screened with qPCR-1 for genotype 1 DNA as
EDTA-plasma maxipools of 480 units each. Nucleic acid eluates of 292 such maxipools,
altogether representing 140 160 blood donation units, were randomly selected and studied
with qPCR-2.
Of maxi pools collected during 2002-3, 11 single donations with high-titer B19 DNA
(determined by qPCR-1) were available for genotyping. Since phenol-based extraction is
not recommended for qPCR-2, one of the recommended methods, QIAamp DNA Mini kit
(Qiagen GmbH, Hilden, Germany) was used in parallel. The DNA extracts were studied
with qPCR-2, and the B19 genotype was determined by melting curve analysis. To detect
possible DNA polymerase inhibitors in these preparations, internal control (IC) provided
in each kit was added to the master mix (0.5 ?l / reaction) and detected on channel F3. For
Genotype  Source Insert GenBank
no
Plasmid backbone
pB19-Lit 1 Serum  1-5300 AY504945 Litmus29 (New England
Biolabs, Beverly, USA)
pLaLi1 2 Skin 105-1312 AY044266 Litmus29
pLaLi2 2 Skin 1092-2332 AY044266 Litmus29
pLaLi3 2 Skin 2058-3121 AY044266 pSTBlue-1 (Novagen,
Madison Wisconsin, USA)
pLaLi6 2 Skin 105-3121 AY044266 pSTBlue-1
pV9-C22* 3 Serum /
BM
1-5028 AJ249437 a modified plasmid
pcDNA2.1 (Invitrogen Life
Technologies, Paisley, UK)
pD91.1-C10* 3 Serum 1-5028 AY083234 pcDNA3.1HisB (Invitrogen)
41
comparison, both DNA extracts were additionally studied by the conventional VP1-PCR
and K71-PCR assays.
Tissue samples: To  determine  the  prevalence  of  B19  type  2  DNA  among  the  synovial
tissue and skin, all the tissue samples that had earlier been examined by the qualitative
NS1-, VP1- and VP2-PCRs were studied further with the genotype 2-specific K71-PCR.
B19 type 3 was not examined.
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Biological and immunological relations of B19 genotypes 1-3 (IV)
Assay for measuring promoter activities
Construction of the promoter-luciferase vectors: The full-length p6 promoter regions (nt.
195-623 according to the NAN reference sequence, GenBank accession number
AY504945)  were  amplified  by  PCR  from  viremic  serum  NAN  (genotype  1),  from  skin
sample LaLi (genotype 2), and from viremic serum D91.1 (genotype 3) (Servant et al.,
2002). The p6 regions of genotypes 2 and 3 were amplified by PCR in two steps. In step
one, two overlapping PCR amplicons of each genotype were produced: one with primers
NheIfwd (modified from (Gareus et al., 1998)) and B19RNArev (table 2), and the other
with primer prom5fwd and xhorev for genotype 2, and prom5fwd and xhoD91.1rev for
genotype 3. The two PCR products were excised and purified from the agarose gel with a
gel-extraction kit (Qiagen and Sigma, St. Louis, USA). In step 2, the purified products
were combined by using as template the two overlapping products in a PCR reaction
performed with the primers NheIfwd and xhorev (genotype 2) or NheIfwd and
xhoD91.1rev (genotype 3). The final products were subsequently integrated into NheI and
XhoI cloning sites of the plasmid pGL3basic containing a firefly (Photinus pyralis)
luciferase as reporter (Promega Corporation, Madison, WI, USA). Inserts of the three
promoter-luciferase constructs were sequenced at the core facility of the Haartman
Institute (University of Helsinki, Finland) by the ABI PRISM technique.
Transfections: For  measurement  of  promoter  strengths  of  the  three  virus  types,  the
three p6 promoter constructs were transfected into several cell lines permissive and non-
permissive for B19. As an internal reference, production of a second type of luciferase
derived from Renilla reniformis was  achieved  by  co-transfecting  a  plasmid  pRL-TK
(Promega) to the cells together with the promoter-luciferase constructs. Cell-lines and
transfections are described in table 4.
Measurements: The cells were collected one day post transfection, and a 20-µl sample
of the lysate was used for quantification of the luciferase activity. Each sample was
assayed in duplicate. The assays for the Photinus and Renilla luciferase activities were
performed sequentially with a Dual-Luciferase Reporter assay system (Promega) as
recommended by the manufacturer. The expression of the test and the control reporters
were measured by a Digene DCR-1 luminometer (MG Instruments Inc., Hamden, CT,
USA)  in  relative  luminescence  units  (RLU)  during  a  period  of  ten  seconds  for  each
luciferase. Experimental RLU was normalized to the activity of the control RLU to
minimize inter-reaction variability caused by differences in cell viability or transfection
efficiency.
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Controls: In all experiments, the vector pGL3control, which contains the firefly
luciferase gene under control of the simian virus 40 (SV40) promoter and enhancer
sequences, was used as positive control. To compare the activities of the different p6-
promoter constructs within the different cell lines, the activity of the SV40 promoter was
set  at  1  in  all  cell  types.  The  RLU  of  each  virus  type  (normalized  against  the  Renilla
standard) was divided with the normalized RLU of the pGL3control. Water and empty
vector pGL3basic were used as negative controls. All transfection experiments were
performed at least three times.
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Table 4. Cell-lines and transfection methods used.
All media contained penicillin, streptomycin and L-glutamine, and the cells were grown in 5% CO2 at 37°C.
Cell line Cell type Maintained in: Transfection:
KU812Ep6 Erythroid leukemia cells RPMI 1640, 10% FBS, 6 U/ml erythropoietin Electroporation: 350 V, 960 ?F;
2 ?g reporter construct, 0.2 ?g pRL-TK
UT7/Epo-S1 Erythroblastoid cells IMDM, 10% FBS, 2 U/ml erythropoietin Electroporation: 350 V, 960 ?F;
2 ?g reporter construct, 0.2 ?g pRL-TK
MB-02 Megakaryocytic leukemia
cells
RPMI 1640, 10% human serum, 200 U/ml GM-
CSF
Electroporation: 300 V, 960 ?F;
2 ?g reporter construct, 0.2 ?g pRL-TK
U937 Monocytic cells RPMI 1640, 10% FBS, 10 mM HEPES, 1mM
sodium pyruvate, 4.5 mg/ml glucose, 1.5 mg/ml
sodium carbonate, 4U/ml erythropoietin, 25 ng/ml
hSCF
Electroporation: 350 V, 960 ?F;
2 ?g reporter construct, 0.2 ?g pRL-TK
HUH-7 Hepatocytes MEM Lipofectamine 2000;
1.6 ?g reporter, 0.16 ?g pRL-TK
HaCaT Keratinocytes DMEM, 10% FBS Lipofectamine 2000;
2.0 ?g reporter, 0.2 ?g pRL-TK
HeLa Cervical epithelial cells MEM Lipofectamine 2000;
0.8 ?g reporter, 0.08 ?g pRL-TK
HeLa/pGRE
HeLa/pGRE.NS
HeLa-cells expressing the
B19 type-1 NS1 protein
when induced by 1mM
dexamethasone
MEM, 300 ?g/ml hybromycin B Lipofectamine 2000;
0.8 ?g reporter, 0.08 ?g pRL-TK
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Recombinant expression and purification of virus type 1 and 2 capsids (IV)
A baculovirus expression method (Brown et al., 1991) was used for production of
recombinant capsids of B19 type 1 and 2. The synthesis of B19 type 1 recombinant
capsids has been reported before (Franssila et al., 2001). Virus-like particles (VLPs) of
B19 virus type 2, composed either of capsid protein VP2 alone or of proteins VP1 and
VP2 together, were synthesized with a similar protocol. The VP2 and VP1 genes of virus
type 2 were amplified by PCR with primers KK1-KK4 (Table 2) using as template a virus
type-2 clone (LaLi) in a pSTBlue-1 vector (Novagen, Madison, WI). The amplified VP1
and VP2 genes were cloned into the baculovirus transfer vector pAcuW51 (Pharmingen,
San Diego, CA, USA) under the control of the p10 and polyhedrin promoters,
respectively. The recombinant VP2 and VP1/2 plasmids together with linearized
baculovirus DNA (Baculogold; Pharmingen) were co-transfected into Sf9 cells with
Fugene6 TM transfection reagent (Roche Diagnostics, Indianapolis, IN, USA). The
production of viral proteins was determined by SDS-PAGE and Western-blotting, and the
formation of VLPs was verified by EM. The recombinant VP2 or VP1/2 capsids of B19
types 1 and 2 were produced in large scale in High Five™ cells and were purified with 28
% (w/w) CsCl-gradient ultracentrifugation (100 000 x g for 48 h at +4°C) followed by
precipitation with 40 % ammonium sulfate.
Hemagglutination assay
In order to detect and compare the quantities of the viral particles in the viremic serum
samples SPR3 (genotype 1), IM-81 (genotype 2) and D91.1 (genotype 3), a
hemagglutination assay (HA) was performed (Brown and Cohen, 1992). Recombinant
capsids, produced with the baculovirus system, were used to set up the HA: human
erythrocytes (obtained from FRC-BTS) were washed three times and suspended (10 %
v/v) in PBS. The suspension was further diluted 1:20 in HA-buffer (NaCl 8 g/l, 0.2 g/l
KCl, 5 g/l dextrose and 0.2% BSA in 0.05M PBS, pH 5.8), and 50 ?l of the suspension
was added to each well on a 96-well plate. Serial three-fold dilutions of viremic sera were
prepared in HA-buffer, and 50 ?l of each dilution was added to the plates and incubated
for two hours at 4°C.
Infectivity assay
KU812Ep6 or UT7 /EpoS1 cells were suspended in media containing the viremic sera of
types 1, 2 or 3. After incubation for 2 h at 37ºC (KU812Ep6 cells) or 2.5 h on ice
(UT7/Epo-S1 cells), fresh medium was added to obtain a final density of 0,2x106 cells/ml.
Infection was monitored on day 3 with immunofluorescence (IF), as described in IV, and
RT-PCR, as described in Brunstein et al. (2000).
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Enzyme immunoassays
Four different EIAs, using as antigen biotinylated VP2 or VP1/2 capsids of B19 types 1 or
2, were set up (as described in (Kaikkonen et al., 1999)) for comparison of antibody
activities of B19 type 1- or type 2- infected subjects. The optimal concentrations of each
antigen preparation (40 ng/well for type 1 VP2, 80 ng/well for type 1 VP1/2, 80 ng/well
for type 2 VP2 and 100 ng/well for type 2 VP1/2) were first determined by end-point
titration. The four antigens were then tested with dilutions of the WHO International
standard for Anti-Parvovirus B19 serum IgG (NIBSC 93/724) (Ferguson et al., 1997). In
addition, all antigens were tested with acute-phase (low avidity of IgG, acute epitope-type
specificity) and past-immunity (high avidity of IgG, non-acute epitope-type specificity)
human serum pools (Kaikkonen et al., 1999; Soderlund et al., 1995a; Soderlund et al.,
1995b).
 To examine the extent of IgG cross-reactivity between virus types 1 and 2, three
groups of sera were studied: group 1 contained the sera of 24 subjects persistently carrying
B19  DNA  of  type  1  in  skin  and/or  synovial  tissue;  group  2  contained  the  sera  of  25
subjects carrying B19 DNA of type 2; and group 3 contained the sera of 13 B19-IgG-
negative subjects. The group-3 IgG-negative samples were used to set the EIA cut-offs
(mean + 3 x SD).
The subjects in groups 1-3 were healthy members of hospital or laboratory staff, or
patients with trauma or other B19-nonrelated disease, and either skin or synovial tissue
samples derived from these subjects had been previously examined for B19 DNA
persistence (I, II). All the sera had been studied for B19-IgG and IgM antibodies by in-
house (Kaikkonen et al., 1999) and commercial (Biotrin, Dublin, Ireland) EIAs,
respectively, and for VP2-IgG epitope-type specificity (Kaikkonen et al., 1999; Soderlund
et al., 1995b) and VP1-IgG avidity (Soderlund et al., 1995a), for verification of long-term
immunity.
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Results
B19 DNA in tissues (I & II)
VP1 PCR
Samples of synovial tissue (I) and skin (II) were screened for B19 DNA by amplifying a
fragment in the middle of the genome, covering the junction of NS1 and VP genes (VP1
PCR). Blood samples taken from the same patients were studied for B19 antibodies (Table
5).
In study I we had both synovial tissue and serum from 12 B19-seronegative and 18
B19-seropositive subjects. Of the latter group, 16 had B19-IgG but no B19-IgM, and 2
patients had both B19-IgG and IgM. Among the 18 B19-seropositive patients, 12/18 (67
%)  had  B19  DNA  in  synovia,  whereas  all  the  seronegative  subjects  were  negative  for
synovial B19 DNA. In study II we used skin and serum samples from 15 B19-
seronegative and from 19 B19-seropositive subjects with past immunity (IgG+ with non-
acute epitope-type specificity and IgM-). Among the 19 seropositive subjects 14/19 (74%)
were VP1-DNA positive in skin, whereas all the seronegative subjects were B19 VP1-
DNA negative by PCR in skin.  Thus,  every patient  with B19 DNA in synovium or skin
had been infected with the virus.
Of the B19 DNA-positive synovia we chose randomly for further examination four
cases representing long-term carriership of B19-DNA (positive IgG, negative IgM, “non-
acute” ETS patterns) and for comparison both 2 cases with serological evidence for recent
B19 infection (positive IgG, positive IgM, “acute” ETS patterns). The six samples chosen
for further study were titrated serially in 10-fold steps for VP1-PCR positivity. Of the skin
samples, all 14 B19-DNA positive samples were studied further.
NS1 and VP2 PCR
Synovial samples (I): In study I, to assess whether the tissues contain the entire B19
coding region, the last dilutions of synovial DNA preparations giving a positive VP1
signal  (“end-point  titers”)  were  used  as  a  template  in  PCR assays  for  the  VP2 and NS1
genes. The entire protein coding area of the B19 genome could be found in all the 6
samples. With 5 of these samples, the last dilution that was positive in VP1-PCR gave a
positive  result  also  in  VP2-  and NS1-PCR assays.  With  the  one  sample  positive  in  VP1
PCR in dilutions up to 1:10 000, the NS1 and VP2 regions could be detected in dilutions
up to 1:1000. To assess whether the DNA is intact or fragmented, both ends of the coding
region were co-amplified in end-point diluted templates. Both the NS1 and the VP2
regions were simultaneously detectable in all four samples studied.
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Skin samples (II): In study II, among the VP1-positive dermal samples only 5/14 gave the
expected positive results in the B19 NS1- and VP2- PCRs, whereas the remaining 9/14
samples showed poorly reproducible amplicons or weak hybridization signals, when using
standard B19 probes, even with undiluted DNA preparations (Table 5.).
Table 5. Results of antibody testing and B19 specific PCRs.
B19 serology VP1-PCR NS1-PCR VP2-PCR Number
Synovia IgG+, IgM- + + + 10
- - - 6
IgG+, IgM+ + + + 2
IgG-, IgM- - ND ND 12
total 30
Skin IgG+, IgM- + + + 5
+ - - 9
- - - 5
IgG-, IgM- - ND ND 15
total 34
Analysis of the B19 genomes in tissue
Synovial tissue samples (I): Of  the  4  synovial  tissue  samples  (I),  nearly  complete
sequences were obtained. In all, ~97 % of the B19 coding region (of 4355 nucleotides
with the Au strain, corresponding to a coding sequence of 4362 nucleotides) was
sequenced from each of the 4 isolates (Kati 1-Kati 4). The synovial sequences were
compared with the blood-derived reference sequences Au (M13178) and Wi (M24682).
Both in our patients with recent infection and in our subjects with past immunity, the
sequence identity relative to the Au reference was >99%. Altogether, our synovial
sequences differed from either reference (Au or Wi) by 27 conserved (occurring in every
subject studied) nucleotide changes. Yet, all our conserved changes relative to either
reference strain were found to agree with the other reference strain. Of the 9 conserved
changes relative to Au, 5 were within the NS gene and 4 within the VP1/2 gene. While 6
of those mutations were silent, 3 changed an amino acid; nt 692 converted threonine into
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isoleucine, nt 3809 converted serine into threonine, and nt 3182 converted serine into
proline. Conversely, our synovial sequences differed from the Wi reference in 18
conserved changes. For all those 18 nucleotides our sequences were identical with the Au
reference.The Au and Wi references differ from each other by 35 nucleotides within the
region sequenced here. For the 8 nucleotides beyond those 27 described above, all our
sequences individually followed either the Au or the Wi reference.
We next examined our sequence data for evidence of nonconserved mutations that
might functionally inactivate the B19 proteins. Throughout our samples, nonsilent
mutations were rare, comprising <25 % of all nucleotide differences. No stop-codons,
frame-shifts, insertions or deletions were found.
Skin samples (II): The weakly hybridising PCR products from 4 subjects were sequenced
directly, and 2 subjects´ DNA preparations underwent several additional PCRs for cloning
and sequencing. From one B19 DNA isolate we sequenced nucleotides 144-4763 (LaLi,
AY044266), and from the other (HaAM) nucleotides 144-1510 and 2134-4763 (GenBank
AY044267 and AY044268, respectively) (numbering according to the Au reference;
M13178).
Within the overall coding region, LaLi-sequence differed from Au by 10.8%.
Divergence within the different parts of the protein coding region of LaLi, in comparison
with the B19 Au, Wi (M24682) and V9 (AJ249437) sequences, at DNA and amino acid
levels are shown in table 6. The two isolates (LaLi and HaAM) differed from each other
by only 0.3%.
The most striking nucleotide variation was seen between the non-coding regions,
where the sequence of LaLi differed from the Au reference by 26.5 %. This region covers
partly the p6 promoter area. In addition to extensive nucleotide variation, alignment of the
p6 regions of B19 types 1-3 revealed an 8 nt deletion, comprising majority of one of the
two tandemly arranged GC-boxes upstream of the TATA-box (Figure 6). Since these
changes might alter the promoter function, the p6 promoters of the three B19 genotypes
were later amplified, cloned and sequenced in full length (IV), and their activities were
measured (see Biological relations of B19 types 1-3).
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Table 6. Sequence divergences (%) between the different B19 genotypes (the prototypic
B19 genotype represented by isolates Au and Wi, genotype 2 represented by isolate LaLi,
and genotype 3 reresented by V9).
1) Divergences were obtained by the Distances (with no corrections) program of the Wisconsin Package of
GCG.
2) CDS stands for the total protein coding sequence (nucleotides 436-4789).
DNA 1) non-cds 2) cds 2) NS1 VP1/2 VP2 uVP1
LaLi vs Au 26,5 11,8 14,3 9,7 11,9 4,7
LaLi vs V9 17,2 9,3 8,1 10,3 10,9 8,8
V9 vs Au 30,7 13,9 15 12,9 14,5 9,1
Au vs Wi 1,6 0,8 0,7 0,9 1 0,6
Protein NS1 VP1/2 VP2 uVP1
LaLi vs Au 6,2 2,4 1,5 4,5
LaLi vs V9 3 2,8 1,3 6,4
V9 vs Au 6,1 3,3 1,8 6,9
Au vs Wi 0,7 0,6 0,4 1,3
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Type 2 AAGC--GCTGGCCCAGAGCCAACCCTAATTCCGGAAGTCCCGCCCACCGGAAGTGACGTC
type 3 AAGC--GCTGGCCCAGAGCCAACCCTAATTCCGGAAGTCCCGCCCACCGGAAGTGACGTC
type 1 AAGCAAGCTGGCCCAGAGCCAACCCTAATTCCGGAAGTCCCGCCCACCGGAAGTGACGTC
type 2 ACAGGAAATGACGTCACAGGAAATGACGTAGTTGTCCGCCATCTTGTACCGGAAGTCCCG
type 3 ACAGGAAATGACGTCACAGGAAATGACGTAACTGTCCGCCATCTTGAACCGGAAGTCCCG
type 1 ACAGGAAATGACGTCACAGGAAATGACGTAATTGTCCGCCATCTTGTACCGGAAGTCCCG
type 2 CCTACCGGCGGCGACCGGCGGCATCTGATTTGGTGTCTTCTTTT--AAATTTTCGCGGGC
type 3 CCTACCGGCGGCGACCGGCGGCATCTGATTTGGTGTCTTCTTTTTAAAATTTTTGGCGGG
type 1 CCTACCGGCGGCGACCGGCGGCATCTGATTTGGTGTCTTCTTTT---AAATTTTAGCGGG
type 2 TTTTTTCCCGCCTTATGCAAATAACCTGCCATGTTTGATGCTTTATTTTAATTTGATTGG
type 3 CTTTTTCCCGCCTTATGCAAATGAACAGCCATGTTTGGTGTATTATTTTAATTTTATTGG
type 1 CTTTTTCCCGCCTTATGCAAATGGGCAGCCATTTTAAGTGTTTTACTATAATTTTATTGG
type 2 ACAAAAACTTAACGGTTTTTATGGGCGGAGT-TACGC-------ATGGTATATA-AGCAG
type 3 ACACAGGCCTAACGGTTATTATAGGCGGAGT-TACGG-------ACAGTATATA-AGCAG
type 1 TTAGTTTTGTAACGGTTAAAATGGGCGGAGCGTAGGCGGGGATTACAGTATATATAGCAC
type 2 ATGAATTCTGTACAACTTTCTTTCCTGGCTGCTTTTTACTGGGAATAACTTGCTGTTATT
type 3 CTGAGTTTCGTGACACTTTCTTTTCTGGTTGCTTCTTACTGGAACTCACTTGCTGTTATT
type 1 GGAACTGTCGCAGCTCTTTCTTTCTGGGCTGCTTTTTCCTGG-ACTTTCTTGCTGTTTTT
type 2 TGCCTGCTAATTAACAGGTATTTATACTAACTTTTAATTTACTAACatg
type 3 TGCCTGCTAACTAACAGGTATTTATACTAACTTTTAACTTACTAACatg
type 1 TGTGAGCTAACTAACAGGTATTTATACTACTTGTTAACATACTAACatg
Figure 5. Alignment of the cloned  p6 promoter regions of B19 type 1 (NAN), type 2 (LaLi) and
type 3 (D91.1), by Clustal W (1.82). Binding sites for cellular factors (Sp1, Sp3, YY1, MZF1,
E4BP4, Oct-1and ETS-proteins), and the TATA-box are marked with boxes as shown in Gareus et
al. 1998 and Servant et al. 2002.
Seeking additional evidence of genetic clustering and abnormal variation of the dermal
B19 isolates, the LaLi sequence was aligned with 13 B19 sequences from GenBank,
including the blood-derived reference Au, and the four synovial B19 sequences (I), the
variant V9 (Nguyen et al., 1999); and a Simian parvovirus (Brown et al., 1995). A
phylogenetic tree based on these data was constructed (Figure 2 in II). The B19 isolates
from blood and synovial tissue formed a condensed cluster except for the two variants
LaLi and V9 that remained outside the B19 group, and apart from each other.
TATA-boxMZF1SP1/3SP1/3YY1E4BP4
YY1OctamerSP1
SP1c-ETSYY1c-ETS
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Methods for detection of the B19 variants (II & III)
Development of genotype 2-specific PCR
A B19 type 2-specific PCR (K71-PCR) was designed according to the newly found LaLi-
sequence (II). All the skin and synovial tissue samples were studied again, this time with
K71-PCR. DNA of B19 type 2 was detected from the 9 skin samples that gave unclear
results with VP2- and NS1-PCRs, but not in those 5 samples that were clearly positive
with all the three B19 PCRs designed according to the B19 prototype sequence. The 6
samples from B19-seropositive but VP1-PCR negative subjects as well as the 15 B19-
seronegative subjects remained negative with K71-PCR. Additionally, 16 synovial
samples previously tested positive for the conventional NS1-, VP1-, and VP2-PCRs, were
studied for genotype 2 DNA: all were negative. The VP1-PCR was thus shown to detect
both the prototype (genotype 1) and the new variant, LaLi (genotype 2), whereas K71-
PCR was shown to be specific for the LaLi-variant representing genotype 2.
Table 7. PCR  results  of  the  skin  samples.  All  the  samples  that  gave  positive  results  in
VP1-, NS1- and VP2-PCRs remained negative by the B19 type 2-specific K71-PCR.
B19 serology VP1-PCR NS1-PCR VP2-PCR K71-PCR Number
IgG+, IgM- + + + - 5
+ - - + 9
- - - - 5
IgG-, IgM- - - - - 15
total 34
Construction of plasmids for qPCR evaluation
Several plasmid constructs carrying B19-virus DNA of the different genotypes were used
for evaluation of the two commercially available B19 qPCR methods. The concentrations
of plasmid purifications were equalized and verified by dot-blotting serial (1:2) dilutions
of each preparation onto a nylon membrane and hybridizing with a digoxigenin-labelled
probe against the plasmid backbone (Figure 6).
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Figure 6. Dot-blot of serially diluted plasmid preparations.
The LightCycler-Parvovirus B19 quantification kit (Roche Diagnostics), qPCR-1, was
highly sensitive for genotype 1 DNA detection. When tested with plasmid constructs, a
positive  signal  was  obtained  even  with  a  theoretical  load  of  0.5  copy  /  reaction.
Quantification of genotype 1 was accurate down to 50 copies / reaction. However, this
method barely recognized genotype 2: in two out of four parallel runs, a positive signal
was obtained only with >5 million copies of pLaLi1 / reaction. Higher dilutions remained
negative in every run. The qPCR-1 assay was tested further with plasmid pLaLi2 and
plasmid pLaLi6 containing the full NS region, and the results were similar. Of the two
genotype-3 isolates, only V9 was recognized, with a sensitivity of approximately 1 log
lower than for genotype 1. The signal for the genotype-3 isolate D91.1 remained negative
even with 5x109 copies / reaction. Melting curve analysis of qPCR-1 products showed the
same two peaks (63.27 °C and 69.5 °C) for all amplicons regardless of genotype (data not
shown). Thus, the three B19 genotypes could not be differentiated from each other by
melting-curve analysis after qPCR-1.
To examine the suitability of the qPCR tests for identification of the three genotypes
under natural condition, clinical samples previously shown to contain genotypes 1 (4 skin
biopsies), 2 (6 skin biopsies) or 3 (2 serum samples), were analyzed. Because of the low
B19-DNA level in these samples and because of the presence of inhibitory compounds in
the phenol-chloroform extracted DNA preparations, as indicated by the absence of an
internal control (IC) signal in some of the replicates, both undiluted and 1:10-diluted
samples needed to be tested. qPCR-1 recognized 2/2 skin samples containing B19 DNA of
genotype 1. All 5 skin samples containing genotype 2 and both serum samples containing
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the two different subtypes of genotype 3 remained negative, even though the IC gave a
positive signal indicating absence of PCR inhibition.
The RealArt Parvo B19 LC PCR (Artus GmbH), qPCR-2, recognized genotypes 1, 2
and isolate V9 of genotype 3 with equal sensitivity. All three were detected in copy
numbers down to 5 / reaction. However, the detection sensitivity for the genotype 3 isolate
D91.1 was ~ 3 log lower, with a detection limit of 5000 copies / reaction.
Melting-curve analysis distinguished all three genotypes, although Tm variation
among samples of each genotype was relatively high. The Tm for genotype 1, genotype 2,
and both subtypes of genotype 3 were 67.57 (66.53 – 68.45), 65.34 (64.72 – 65.77) and
60.69 (59.94 – 61.34) °C, respectively. However, a mixture of all three genotypes resulted
in  only  two peaks  characteristic  of  genotypes  1  and 3.  If  two genotypes  were  present  in
one sample, genotypes 1 and 2 showed only one peak (characteristic of genotype 1) and
were not distinguished by this method; whereas both other genotype combinations, 1 and
3 as well as 2 and 3, showed the correct two peaks. The corresponding melting points were
independent of DNA load. The WHO International Standard (99/800) that was used as a
positive control, showed a single melting peak of 67.5, which is characteristic of genotype
1.
In agreement with the results obtained for plasmid templates, qPCR-2 recognized all
genotypes in clinical samples: genotype 1 in 4/4 skin samples, genotype 2 in 6/6 skin
samples, and genotype 3 subtype D91.1 in 1/1 serum sample.  As with qPCR-1, the serum
containing isolate V9 of genotype 3 remained negative even though the internal control
was positive. All the three genotypes in the clinical samples could be differentiated by
melting curve analysis.
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Prevalence of B19 types 1-3
In blood: During January 2002 and April 2003, 857 maxipools were pre-screened for B19
DNA by qPCR-1 at the Finnish Red Cross Blood Service. Within the 857 pools, 580 (67.7
%)  were  negative  for  B19  DNA.  Of  the  277  positive  pools,  13  (1.6  %  of  total  pools)
contained a high concentration (>104 IU/ml)  of  B19  DNA,  and  were  excluded  from the
production pools (Fig. 7).
Figure 7. Results of pre-screening of maxipools for B19 DNA with qPCR-1 (Roche).
Of the 857 pre-screened pools, 292 were randomly selected and studied with qPCR-2.
The samples could be divided in 4 groups: 13/292 (4.5 %) were qPCR-positive with both
tests (sample group 1), 3/292 (1.0 %) were qPCR-1 negative but qPCR-2 positive (group
2), and 51/292 (17.5 %) were qPCR-1 positive but qPCR-2 negative (group 3). Majority of
the maxipools, 225/292 (77.1 %), were negative with both qPCRs (group 4). To verify the
qPCR-2 genotype identification in each maxipool, samples positive with qPCR-2 were
studied further with the conventional PCRs, VP1-PCR and the genotype 2-specific K71-
PCR (Table 2. in III).
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Within the 13 samples in group 1, seven were positive by VP1-PCR and all were
negative by K71-PCR. By melting curve analysis following qPCR-2, most samples (9/13)
gave results corresponding to genotype 1. However, four samples gave melting points of ~
63.6 °C, i.e. intermediary between the melting points characteristic for genotypes 2 and 3.
Within this group the viral loads – as determined by the qPCR-1 CP value – were over 105
IU/ml in one sample, 104-105 IU/ml in 2 samples, 103-104 in four samples, and <103 IU/ml
in six samples. The six VP1 PCR-negative samples were those from the last category.
The three qPCR-1-negative samples in Group 2 gave a weak positive signal (barely
showing a curve) with qPCR-2, and were completely negative by VP1-PCR and K71-
PCR. The melting point for one of these three samples was positioned at ~63 °C like the
four samples in group 1, and another sample showed a melting point typical for genotype
1 (68 °C). No melting point could be observed for the third sample. The five samples of
groups 1 and 2 with unusual melting points were retested with qPCR-2 with reproducible
results. The qPCR-2 test gave concentration values for seven more qPCR-1-negative
samples, which were however considered negative due to the lack of any visible
amplification (or melting) curves.
Among the 51 samples of group 3 (positive by qPCR-1 alone) the B19-DNA loads
were low, <103 IU/ml in 50 samples and 103-104 IU/ml  in  one  sample.  All  samples  had
been pre-screened with qPCR-1 soon after collection (non-frozen), and had been stored
frozen at –20°C (with two thawings) before qPCR-2 testing. The reason for the negative
results of qPCR-2 in group 3 might thus be degradation of low-level B19 DNA.
Of the 13 (single) blood donations excluded from manufacture due to excessive B19-
DNA levels by qPCR-1, 11 were still available for testing, and were found positive by
qPCR-2. The QIAamp DNA Mini Kit -purified samples showed a DNA concentration
slightly (? 1 log) higher than the same samples extracted by phenol-chloroform. When the
phenol-chloroform-extracted samples were diluted 1:100 in PCR-grade water, the melting
points for all samples except one were characteristic for genotype 1, with an average Tm
of 67.41 °C (67.23 – 67.51). With undiluted samples the melting points were unusually
low, 64.9 °C (61.81-65.97). However, the melting point for one sample (#7) remained
between the positions of genotypes 2 and 3 (Tm ~63 °C) even after dilution. When DNA
of these same samples was extracted with QIAamp DNA Mini Kit, all showed melting
points typical for genotype 1 even undiluted, except plasma #7, which gave the unusual
melting point of 63 °C with this extraction method as well. By sequencing, this sample
was subsequently shown to contain B19 type 1.
In tissue: All  the  skin  (N=34)  samples,  and  synovial  tissue  samples,  previously  tested
positive by NS1-, VP1- and VP2-PCRs (N=16), were studied with NS1-gene primers
specific for the new genotype (K71). DNA of B19 type 2 was detected from skin in 9/19
B19-seropositive and in 0/15 B19-seronegative subjects (table 7.). All in all, in skin, B19
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type 2 DNA was more prevalent (47 %) than the prototypic B19 DNA (26 %).  In
synovium, prototypic B19 DNA was detected in 67 % of the seropositive samples, while
type 2 DNA was absent.
Biological and immunological relations of genotypes 1-3 (IV)
Promoter activity
To examine the impact of the >20% sequence diversity within the p6 promoter region on
the biological activity or cell tropism of the variant viruses, the p6 promoter strengths of
all three virus types was measured in a variety of cell types, in proportion to the strength
of the SV40 promoter. In concordance with earlier studies (Gareus et al., 1998), the B19
promoters were most active in the permissive cells. In all other cell types the promoters of
the three B19 genotypes were of similar strength, except in HaCaT cells, in which the type
1 promoter was ~3 fold stronger than those of genotypes 2 and 3. The difference was
reproducible (Figure 1 in IV).
To examine whether the NS1 protein of B19 type 1 can enhance the activity of p6 in
all the three B19 types, the promoter-luciferase constructs were transfected to
HeLa/pGRE.NS cells induced with dexamethasone to produce the genotype 1 NS1 protein
(Leruez-Ville et al., 1997). The expression of NS1 protein was verified by IF. Uninduced
HeLa/pGRE.NS cells, and cells containing the native pGRE-vector prior to (HeLA/pGRE)
and following (HeLa/pGRE IND) induction, served as negative controls. The promoter
activities of the three virus types in the presence of NS1 were 3 – 4 times stronger than in
the absence of NS1, with no significant difference between the three virus types (Figure 2
in IV).
Expression of recombinant VP2 and VP1/2 virus-like particles of genotype 2
Sf9 cells were infected with recombinant baculoviruses containing the B19 virus type 2
gene(s) for either VP2 alone or VP1/2 together. With both constructs, SDS-PAGE and
subsequent Western-blotting verified the production of VP1 and VP2 proteins. EM of cell
lysates showed icosahedral, parvovirus-like particles with a diameter of ~23 nm (Figure
8). Both of these VLPs of virus type 2 hemagglutinated human red blood cells and were
thus used, together with those of type 1, to set up EIA-tests for IgG cross-reactivity
studies.
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Figure 8. EM of baculovirus-expressed, purified B19 type-2 VP2 (left) and VP1/2 (right) capsids.
Scale bar 50 nm.
Hemagglutination activity and infectivity of virus types 1-3
To determine the viability of the three B19 genotypes, two myeloid cell lines, KU812Ep6
and UT7/Epo-S1 were infected with virus-type 1, 2 or 3 -containing plasma / sera. These
sera (SPR3, IM-81 and D91.1, respectively) were known to contain B19 DNA, and were
examined further with an hemagglutination assay (HA) to make sure they also contain
viral particles. All samples did hemagglutinate the human erythrocytes at +4?C, pH 5.8.
With the virus type-1 positive serum (SPR3), hemagglutination was observed with DNA
concentrations down to 4.7 x 107 IU/ml;  with  virus  type  2  (IM-81)  down  to  1.7  x  106
IU/ml; and with virus type 3 (D91.1) down to 5.5 x 105 IU/ml (Figure 3 in IV). The
corresponding HA-titers were 14400, 14400 and 8700, respectively.
All three genotypes were able to infect the two cell lines (KU812Ep6 and UT7/Epo-
S1). IF showed both NS1 and VP proteins in KU812Ep6 infected with virus types 1-3, and
in UT7/Epo-S1 cells infected with virus types 1 and 2. In UT7/Epo-S1 cells infected with
virus type 3, IF verified only capsid protein production due to the scarcity of type 3 serum
(Figure 4 in IV). RT-PCR showed the synthesis of spliced messenger-RNA in both cell
types infected with any of the three B19 types.
Enzyme immunoassays
To examine the immunological relation of B19 virus types 1 and 2, four IgG-EIAs, using
as antigen VP2 or VP1/2 capsids of either virus type, were set up. Sera from three groups
of subjects were examined with the four EIAs: group 1 contained sera from subjects
carrying in their tissues B19 type 1 DNA (n=24), group 2 contained sera from subjects
carrying in their tissues type 2 DNA (n=25), and group 3 contained sera from B19 IgG
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negative subjects (n=13). Cross-reactivity of 100 % was observed between genotypes 1
and 2. The mean absorbance values for the three serum groups are shown in table 8. With
one sample (a type 2 serum), the type 2 VP2 EIA absorbance remained below threshold.
The overall absorbances with this antigen remained lower than with the other three
antigens, irrespective of the antigen concentration or of the genotype specificity of the
serum used. All the antigens were equally reactive with the acute-infection and the past-
immunity serum pools.
Table 8. IgG reactivity with VP2 or VP1/2 capsids of sera from subjects with B19 DNA
of types 1 or 2, in tissue, or from seronegative subjects. The range of absorbance values
obtained with individual serum samples and the calculated mean value for each group of
samples are shown.
ANTIGEN
TYPE1 TYPE2
Sera (dilution 1:200) Absorbance VP2 VP1/2 VP2** VP1/2
40 ng/well 80 ng/well 80 ng/well 100 ng/well
B19 type 1 DNA-carriers mean 2,650 2,698 1,038 2,189
n=24 range 0.867 - 3.838 0.837 - 3.756 0.830 - 1.616 0.822 - 3.032
B19 type 2 DNA-carriers mean 2,588 2,613 1,049 2,142
n=25 range 0.451 - 3.343 0.456 - 3.539 0.134* - 1.358 0.351 - 2.686
NIBSC (1:200)*** mean 2,620 2,827 0,971 2,110
range 2.430 - 2.748 2.710 - 2.895 0.843 - 1.060 1.870 - 2.134
B19 IgG-negatives mean 0,034 0,041 0,045 0,039
n=13 SD 0,028 0,029 0,040 0,036
cut-off
(mean +3SD)
0,119 0,128 0,166 0,146
Acute serum pool 2,858 2,945 1,066 2,271
Past-immunity
serum pool
2,892 3,222 1,018 2,385
*One sample showed borderline reactivity.
**The overall reactivity was equally low for both genotypes.
***International standard for B19 IgG.
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Discussion
Newly found B19 types (II)
For a long time, the B19 DNA sequence was considered extremely stable with a variation
of only ~1-2 %. In 1998, a new B19 variant was found in France, in blood from a child
with severe anemia (Nguyen et al., 1998; Nguyen et al., 1999). Samples of blood and
bone marrow were tested for B19 DNA, but the results were peculiar: a PCR amplicon of
appropriate size could clearly be seen on agarose gel after ethidium bromide staining but it
gave only a faint signal when hybridized with a B19 specific probe. To determine whether
this weak hybridization occurred due to mutations within the probe recognition region, the
PCR products were sequenced and several nucleotide substitutions were seen.
Phylogenetic analysis placed this sequence outside the B19 group, although when
compared to B19 sequences in GenBank, it resembled B19 in FASTA analysis. This
variant, V9, differed from the previously sequenced, prototypic B19 isolates by >10%,
demonstrating that the B19 virus genome is much more divergent than previously
recognized.
In order to determine the molecular characteristics of the B19 virus DNA persisting in
synovial tissue (I) and skin (II), we used the three nested PCR reactions, VP1-, NS1- and
VP2-PCR, which all were based on the two, blood-derived, nearly full-length reference
sequences Au and Wi. While in synovial tissue all VP1-PCR-positive samples were
positive  also  with  the  two  additional  PCRs,  to  our  surprise  many  skin  samples  were
positive by the VP1 PCR alone.  Analysis  of  the other genomic regions revealed a novel
B19 genotype.  Comparative analysis  by BLAST or FASTA of one dermal isolate,  LaLi,
with sequences stored in GenBank or EMBL database showed this new genotype to be
B19-related but different from the blood-derived prototypic B19 sequences and from the
previously published variant V9. At the DNA level, the protein coding sequences differed
by 10.8% from the Au isolate and by 8.6% from V9. Simian parvovirus (SPV), the most
B19-related of the animal parvoviruses, differed from the LaLi isolate by more than 40%.
Simultaneously, with our discovery of variant LaLi in the skin of a healthy adult (II),
B19 isolates of a corresponding DNA sequence were reported by two other groups
(Nguyen et al., 2002; Servant et  al., 2002). The variant A6 was discovered in the USA,
and was by DNA sequence distinct from both B19 prototype and V9, but 98 % similar to
LaLi (Nguyen et  al.,  2002).  In  France,  11  variants  were  found,  two  of  which  in
phylogenetic analysis clustered with LaLi, and the others together with V9, although the
V9-like cluster showed a greater divergence (5.3 % between isolates V9 and D91.1) than
was seen among the prototypic or type 2 sequences (Servant et  al., 2002). Based on
phylogeny, three genotypes of B19 were thus proposed; genotype 1 corresponding to the
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prototype Au-like strains; genotype 2 corresponding to LaLi-like strains; and genotype 3
corresponding to V9-like strains. Some divergence has been detected also within these
genotypes. The genotype-3 cluster of Servant et al. showed a divergence of 5.3 %,
exemplified by the DNA isolates V9 and D91.1 (Servant et al.,  2002).   These  two
genetically distinct subtypes were later identified also among 13 near-full-length
genotype-3 sequences from Ghana, Europe and Brazil, which were named subtypes 3a
(V9-like) and 3b (D91.1-like) (Parsyan et al., 2007). Recently, in Vietnam two subtypes
have been detected also within genotype 1, with a sequence variation of 5-6 % (Toan et
al., 2006).
Figure 9. A phylogenetic tree showing the three B19 genotypes. From Servant et al. (2002), with
permission.
Biological properties of B19 types 1-3 (IV)
When comparing the DNA sequence of the three B19 types, the gene encoding the NS1
protein is more divergent than the genes encoding the two capsid proteins VP1 and VP2.
The divergence is smallest within the unique region of VP1. At the amino acid level, again
the NS1 proteins of B19 types 2 and 3 differ  most,  by 6 %. The VP1 unique regions of
B19 types 2 and 3 differ, at the aa level, by 4.4% and 6.6% compared to the Au isolate,
while the major capsid protein VP2 shows only ~1 % difference. However, a single point
mutation in a viral coding region can alter host-cell tropism or might lead to organ-specific
persistence. The host range determinants of the non-human parvoviruses minute virus of
mice (MVM) and the feline and canine parvoviruses (FPV; CPV) have been characterized
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in detail. Only 2 amino acids of the capsid region determine the lymphoid-cell tropism of
the MVM variant MVMi and the fibroblast tropism of MVMp (Ball-Goodrich and
Tattersall, 1992). Likewise, a change of only a few amino acids yields canine tropism for
FPV (Chang et al., 1992).
The most striking variation is seen within the non-coding region containing the p6
promoter, which differs by >20% (Figure 5). By transient transfection experiments, p6 of
B19 type 1 was shown to be stronger in cell lines permissive for B19 than in cell lines
non-permissive for B19 (Gareus et al., 1998). With recombinant AAV clones, B19 p6 has
been shown to confer autonomous replication competence and erythroid specificity to
AAV (Wang et al., 1995). The promoter strength is regulated by the viral NS1 protein and
by cellular factors (Blundell and Astell, 1989; Liu et al., 1991b; Momoeda et al., 1994a;
Raab et al., 2001; Raab et al., 2002; Vassias et al., 1998). Thus, the extensive divergence
seen  within  the  promoters  of  the  three  B19  types  might  alter  the  extreme  tropism  for
erythroid cells. However, as shown in table 9, besides the B19 prototype, also both of the
B19 variants have been associated with anemia or an aplastic crisis, indicating erythroid
tropism.
In the first infectivity studies of the virus type 2 (isolate A6), RNA transcription could
not be detected with RT-PCR in UT7/Epo-S1 cells (Nguyen et al., 2002). In contrast, in
KU812Ep6 cell culture mRNA expression of types 1 and 2 showed similar kinetics
(Blumel et al., 2005). The p6 promoter activity of virus type 3 had not been studied.
Therefore, we compared the p6 activities of B19 types 1-3. Our results showed that the
promoters of all three virus types were of similar strength (IV) and, in concordance with
earlier studies with the B19 prototype (Gareus et al., 1998), were most active in cell lines
permissive for B19 type 1 infection (IV). The NS1 protein of virus type 1, a known trans-
activator of B19 type 1 promoter (Doerig et al., 1990; Gareus et al., 1998), activated the
promoters of all three types equally.
The self-assembly of structural proteins into capsids had been shown for genotypes 1
(Brown et al., 1991; Franssila et al., 2001) and 3 (Heegaard et al., 2002b). We
demonstrated the same feature for genotype 2 with the capsid proteins VP2 and VP1/2
expressed in the baculovirus system (IV). Electron micrographs revealed icosahedral
particles  with  the  same  diameter  (~23  nm)  as  with  virus  type  1  (Cossart et al., 1975),
which furthermore were able to hemagglutinate human erythrocytes. In the same HA
conditions, the type 1-3 viremic sera were shown, besides DNA, to contain virus particles
with red cell-surface binding activity.
To  further  compare  the  biological  characteristics  and  cell  tropism  of  the  three  B19
types, we infected two cell lines permissive for B19 type 1 with B19 DNA positive sera.
In infectivity experiments, all three virus types induced transcription and maturation
(splicing) of mRNAs and the synthesis of both NS1 and VP proteins in two B19 type 1-
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permissive cell lines. Thus, the results showed that all three B19 types were biologically
active viruses, and suggested similar cell-tropism.
Methods for detection of B19 types 2 and 3
Diagnosis of B19 infection relies on serology and the detection of viral DNA. Several
PCR methods for B19 detection have been published, but as the recent findings of the new
B19 types illustrate, the genome variation among the B19 virus is far more extencive than
previously believed. Due to excessive DNA sequence divergence, most B19 PCR methods
are unlikely to detect these new B19 variants or putative additional genotypes. Clearly,
new methods for detection and differentiation of the new B19 virus variants are needed.
Similarly, the possible immunological cross-reactivity of the three B19 types needed to be
elucidated, to see whether antibodies against one genotype protects from infection of
another, and whether the available serological methods, designed for diagnostics of the
prototypic B19, could also be used to detect antibodies elicited by the new variants.
Immunological cross-reactivity of B19 types 1-3 (IV)
Studies on the antigenic relation between B19 types 1 and 3 have shown a high degree of
cross-reactivity. Heegaard et al. produced, with the baculovirus system, V9-like
recombinant capsids, and screened a panel of 270 clinical samples for the presence of IgM
and  IgG  by  EIA.  The  results  were  compared  to  those  obtained  with  a  commercial  B19
VP2 assay, and revealed a 100 % cross-reactivity between B19 types 1 and 3 (Heegaard et
al., 2002a). The 270 samples, however, presumably did not contain antibodies against B19
type 3, because of the rarity of type 3 infections in Europe. Candotti et al. screened (with a
commercial type-1 VP2-based EIA) samples collected from areas where genotypes 1 (UK)
or 3 (Ghana) are endemic (Candotti et al., 2004), and confirmed the high level of cross-
reactivity between genotype 1- and genotype 3-specific antibodies. However, they found a
small number of B19 DNA-positive samples containing immune complexes that were
undetected by the genotype 1 VP2 antigen, and thus suggested a decreased reactivity of
genotype 3 antibodies with genotype 1 antigen (Candotti et  al., 2004; Parsyan et al.,
2006). Parsyan et al. assessed the ability of genotype 1 or 3 VP2 or VP1/2 capsids to
detect antibodies (Parsyan et al., 2006). They reported a high degree of cross-reactivity
between antigens of B19 types 1 and 3 in samples from UK blood donors and Ghanaian
child populations exposed to B19 types 1 (99.3 %) or 3 (98 %), and in this respect
confirmed and extended the findings of Heegaard et al.
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In vitro neutralization tests using sera from subjects infected with B19 type 1 have
shown inhibition of in-vitro infection of type 2 (Blumel et al., 2005). However, due to a
general lack of methods to distinguish type-2 IgG-positive sera, it has not been possible to
test  if  sera  from  subjects  infected  with  type  2  would  react  with  antigens  of  type  1,  or
whether type 2 antigens are recognized equally well by type-1 sera. Because of our unique
material, sera from subjects infected in the past with either B19 type 1 or type 2 (as
evidenced by persistence of the respective DNAs in tissue), and because of our
recombinant VLPs (VP2 and VP1/2 capsids) of both virus types, we were able to address
this question. Our results revealed a 100 % cross-reactivity in VP1/2- and VP2-EIAs
between virus types 1 and 2 (IV). Such knowledge of cross-reactivity is relevant both for
diagnosis and vaccine development, as well as for the definition of the taxonomic status of
these human erythrovirus variants (Tattersall, 2006). Official classification of ICTV now
places Au (genotype 1), LaLi and A6 (genotype 2), as well as V9 and D91.1 (genotype 3)
as strains of the B19 species (ICTVdB - The Universal Virus Database, version 4.), which
according to the immunological studies of ours and others, seem to constitute a single
serotype.
Qualitative PCR methods
For detection and differentiation of B19 types 1-3, two methods have been published
(Heegaard et al., 2001; Servant et al., 2002). Servant et al. (2002)  performed PCR with
primers allowing for simultaneous amplification of the B19 prototype (genotype 1), LaLi-
like sequences (genotype 2) and V9-like sequences (genotype 3), and used restriction
fragment length polymorphism to identify variant types: the PCR product is digested with
MfeI, for which a recognition site is found in the amplicon of B19 type 1 but is altered in
types 2 or 3. The definitive result is obtained by sequencing. Heegaard et al. used a nested
PCR method, where first-round primers recognize both genotypes 1 and 3, and for
differentiation, distinct nested primers are used (Heegaard et al., 2001) .
In our studies, three nested-PCRs (VP1-, VP2-, and NS1-PCRs) were used to examine
B19 DNA persisting in synovial tissue and skin. Near-full-length genome of five synovial
isolates positive with all  the three PCRs was sequenced,  and shown to be of B19 type 1
(I).  However,  most  of  the  skin-derived  isolates  were  positive  with  VP1-PCR  alone.
Sequencing of two of such dermal isolates revealed genomic DNA of B19 type 2. Thus,
although our three PCR methods detected prototypic B19 DNA in equal sensitivity (I),
which was with plasmid clones determined to be 15 copies per reaction (Norja et al.,
2006), only the VP1-PCR could reliably detect also B19 type 2. To distinguish type 2
from the prototypic B19 DNA, a nested PCR (K71-PCR) was then designed according to
the LaLi-sequence, and was shown to be specific for B19 genotype 2 (II). By using
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plasmid constructs, its detection sensitivity was shown to be 1.5 copies per reaction (Norja
et al., 2006).
qPCR methods for detection of B19 genotypes 1-3 (III)
While the B19 virus has been known for many years, its transmission to recipients of
plasma derivatives despite attempted inactivation has recently reinforced the necessity of
plasma pool screening. All the methods mentioned above can reliably be used for
qualitative detection and/or differentiation of the B19 genotypes but are labourious and
time-consuming and therefore restrict the size of material studied. After the estimation of a
“safe level” of B19 virus DNA after manufacture (European Pharmacopoeia 2004; Brown
et al., 2001) most plasma pool manufacturers have begun to quantify B19 DNA by
nucleic-acid testing to ensure a viral load of <104 IU/ml.
Real-time PCR performs the amplification and detection steps simultaneously in one
tube and when used together with external standards, provide quantitative data. Two
quantitative PCR methods are commercially available and are used for plasma pool
screening. We compared the performance of those two quantitative real-time PCR
methods with plasmids containing DNA of B19 types 1, 2 or 3. In our studies using cloned
DNA of either genotype, qPCR-1 was slightly more sensitive than qPCR-2 in detection
and quantification of B19 genotype 1. In detection and quantification of B19-genotypes 2
and 3, however, qPCR-2 performed better: it detected all three genotypes, although
subtype 3b (represented by isolate D91.1) with lower sensitivity. On the contrary, qPCR-1
did not detect genotype 2, and detected only subtype 3a (represented by isolate V9) of
genotype 3. Similar studies using plasmid constructs were conducted by Baylis et al.
(2004), and their results were in concordance with ours: qPCR-1 detected genotype 1 only,
whereas qPCR-2 detected all genotypes, except subtype 3b with reduced sensitivity.
Additionally, Braham et al. (2004) evaluated qPCR-1 for diagnostic testing and compared
it to a nested PCR and hybridization assays for detection of B19 DNA in clinical
specimens. Among 228 samples, only two sera collected within two weeks from the same
renal transplant patient gave negative results with qPCR-1, although they had earlier been
shown to contain B19 DNA with a nested PCR method. Sequencing of the amplicons and
phylogenetic analysis showed that these samples contained B19 type 2 DNA (Cohen et al.,
2006). In our studies (III), qPCR-2 detected all three genotypes in clinical samples, and
identified them correctly by melting curve analysis. This method in principle allows for
differentiation of specific from non-specific PCR products such as primer-dimers or
mispriming products but can also be used for mutation analysis. Thereby, rapid detection
and differentiation of the three genotypes in a single reaction without labourious
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restriction enzyme analyzes or electrophoretic procedures make qPCR-2 a valuable tool
for rapid genotyping.
Occurrences of B19 types 2 and 3
Even though an increasing number of studies have addressed the role of the B19-virus
prototype (genotype 1) in transfusion of blood and plasma derivatives, knowledge of the
frequency and magnitude of the variant genotypes was scanty. A main reason has been the
lack of suitable tools for the simultaneous detection and distinction of all genotypes. With
a qualitative PCR method for detection and differentiation of B19 types 1 and 3, Heegaard
et al. examined 100 sera containing B19 IgM, and 50 plasma pools, each from 2000
Danish blood donors, without detection of V9 (Heegaard et al., 2001). The same result
came from 190 bone marrow samples of healthy subjects (Heegaard et al., 2002a). To
evaluate the genotype circulation (in France) and frequency among patients of different
entities, Servant et al. screened and genotyped (by PCR, RE-analysis and sequencing)
1084 clinical samples from various sources (Servant et al., 2002). Indeed, LaLi-like
sequences were found in only 2 sera and V9-like sequences in only 9 samples (5 serum, 3
bone marrow, 1 blood), including subtype D91.1 which was detected in serum. With the
same method, Nguyen et al. (2002) examined 149 sera and 18 bone marrows collected in
the USA. Of the 29/149 PCR-positive sera, only one (A6) was of genotype 2, and all the
others of genotype 1. No variants were detected in bone marrow. Upon re-examination of
the Danish blood-donor plasma pools (Heegaard et al., 2002a) and additional pools
(altogether representing 120 000 single donations) only genotype 1 was found.
By a quantitative PCR method, the prevalences of genotypes 1, 2 and 3 among Finnish
blood donors was examined (III). None of the 140 160 blood donations studied contained
B19 genotypes 2 or 3. This result is in concordance with those of Heegaard et al., and
suggests that viremic infections by the “new” genotypes, at present, are extremely rare.
Confirmatory evidence came from recent studies by Norja et al. (2006): altogether 1640
serum samples, collected during 1983-1997 in Finland from patients with rash, fever or
various other constitutional symptoms, also including patients with serologically
confirmed erythema infectiosum, contained exclusively B19 type 1. Similarly, among
1639 clinical samples received for parvovirus diagnosis in the UK (228 during 2001-2002
(Braham et al., 2004) and 1411 during 2003-2005 (Cohen et al., 2006)), only one case of
B19 type 2 and one of type 3 were detected (Cohen et al., 2006). In Germany, virus type 2
was detected in a renal transplant recipient (Liefeldt et al., 2005), in a pregnant woman
(Enders et al., 2006), and in a single plasma donation (Blumel et al., 2005). Nevertheless,
B19 type 2 has been detected in coagulation factor concentrates, albeit in lower frequency
(2.5 %) than B19 type 1 (46.5 %) (Schneider et al., 2004). Candotti et al. screened for B19
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DNA by consensus nested- and quantitative-PCRs, blood donations from the United
Kingdom and three countries of sub-Saharan Africa (Candotti et al., 2004): among plasma
samples from the UK, South Africa and Malawi, 0.55 – 1.25 % contained B19 DNA (42 –
1 x 106 IU/ml), all of type 1. Interestingly, among Ghanaian plasma samples 1.3 % were
positive for B19 DNA (158 - 1.35 x 105 IU/ml), and all findings were of type 3 (Candotti
et al., 2004). Similarly, among pregnant women in Ghana, the prevalence of B19 DNA
was 1.8 %, of which 94 % were of genotype 3 (46 – 3.63 x 106 IU/ml) (Candotti et al.,
2006). Among Ghanaian children, the prevalence of B19 DNA was 11.5 %, all of type 3
(Parsyan et al.,  2006).  Of  the  viremic  children,  ~35  %  were  positive  for  B19  IgM,
indicating acute infection. In Brazil, among 69 bone marrow samples collected from
patients with B19 type 1-related symptoms, ~17 % contained B19 DNA; 5 of type 1; 1 of
type 2; and 6 of type 3 (Sanabani et al., 2006). Of these patients, however, no serological
results were available to determine the time of the primary infection. In Vietnam, B19
DNA was detected in 24 % of 399 plasma samples collected from HBV-infected patients.
Among these subjects, B19 type 1 predominated, type 2 was detected in 4 % of the
samples, while type 3 was absent (Toan et al., 2006). Taken together, viremic occurrence
of B19 type 2 has been observed only very sporadically. B19 type 3 appears to occur
endemically in Ghana and in Brazil, but only occasionally in Europe (Candotti et al.,
2004).
Tissue persistence of the prototypic and recently found B19
variants
The first  aim of this  thesis  work was to examine the integrity of the synovial  B19 DNA
molecules in the acute-phase of infection and in subjects representing long-term
persistence. Since no quantitative PCRs were available, this study was conducted with
three distinct, qualitative PCRs (NS1, VP1, VP2), amplifying different genomic regions
and together covering the complete protein coding sequence. These PCRs were shown to
be of similar sensitivity. By serially diluting the samples, we showed that all parts of the
protein-coding region could be detected at the same, limiting template dilution, suggesting
that  all  genomic  regions  in  the  particular  sample  are  present  in  equimolar  amounts.  In
addition, the fact that the three amplicons are relatively long (? 1000 bp) and that the two
terminal regions of the coding area could be amplified simultaneously in the highly diluted
samples gave further support to the hypothesis that the DNA molecules are retained in
synovium unfragmented. The B19 genome has at both termini long palindromic repeats
(Astell and Blundell, 1989; Deiss et al., 1990; Shade et al., 1986) consisting mainly of GC
base pairs, which together with their hairpin secondary structure provide extremely
difficult targets for PCR detection. We did not examine those noncoding termini.
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However, with an intact full-length coding region present in synovia with no nt
substitutions altering the reading frame (stop-codons, insertions or deletions), viral mRNA
and protein could potentially be produced.
The recently infected individuals and those infected in the past resembled each other
also in the extent of variability of the synovial protein-coding regions of the B19 genome,
albeit none of the sequences were identical. Similarly, within the p6 promoter regions
from 13 synovial tissue samples of hemophiliac patients with chronic synovitis, and 12
acute-phase serum samples from patients with different symptoms (Zakrzewska et al.,
2001), the rates of genomic variability between persistent or acute-phase isolates were not
significantly different.
By sequence analysis, the B19 coding regions that we initially detected in synovium
closely resembled those of two reference strains derived from blood, Au (Shade et al.,
1986) and Wi (Blundell et al., 1987), both of B19 type 1. All the conserved (i.e. found in
all our synovial samples studied) nucleotide changes relative to either reference strain
were found to agree with the other reference. This implied that the genome persistence, as
a phenomenon, in synovial tissue is not related to specific mutations or strain variants.
In skin samples from constitutionally healthy B19 seropositive adults (N=19), virus
type 2 was more prevalent (47%) than the conventional virus type (26%) (II). In sharp
contrast to our preliminary studies, none of the 30 synovial tissue samples studied for
comparison, contained DNA of virus type 2. This led to the presumption of a skin
predilection for genotype 2. The tissue distribution of the B19 variants has been addressed
in subsequent studies: Wong et al. examined livers from patients with fulminant hepatitis
(FH), hepatitis-associated aplastic anemia (HAA), and patients with hepatitis B (HBV) or
C (HCV) infection (Wong et al., 2003). They found B19 DNA in all patient groups;
genotype 2 in 5/30 HBV/HCV patients, and genotype 3 in 1/30 HBV/HCV patients, and in
1/23 FH patients. They also performed RT-PCR to detect B19 transcripts, with negative
results. In studies by Norja et al., B19 DNA was examined in 523 solid tissue biopsies
(synovial tissue, skin, tonsil and liver) collected in Finland or Germany from
constitutionally healthy individuals or from patients with B19 non-related symptoms
(Norja et al., 2006). Both virus types 1 and 2 were found in all tissue types, albeit type 2 at
a lower frequency. In this study, B19 type 3 was not detected. Demographic analysis
showed the occurrence of virus type 1 DNA in subjects  of  all  age groups,  in contrast  to
virus type 2 DNA, which only occurred in those borne before year 1973. Taken together,
the results suggest that B19 types 1 and 2 circulated to an equal extent in northern and
central Europe until the 1960´s, after which type 2 seems to have disappeared from wide
circulation. That the prevalence of persisting B19 DNA was not diminished among the
elderly,  points  to a storage mechanism of life-long capacity both for the B19 type 2 and
the prototype (Norja et al., 2006). Comparable persistence of B19 virus type 3 in solid
tissues of healthy (or diseased) individuals remains to be demonstrated.
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It is still unclear which cell type(s) harbour the tissue-persisting B19 DNA. B19 could
be attached on the surface of follicular dendritic cells or might be carried inside
macrophages. However, life-long tissue persistence, apparently without fragmentation, in
actively hydrolytic cells would seem unlikely.
In addition to erythrocytes, globoside or the blood-group P antigen, the main cellular
receptor for B19 (Brown et al., 1993) and other glycosphingolipids capable of B19 virus
binding, have been detected at several sites and in several cell types (Cooling et al., 1995;
Weigel-Kelley et al., 2001). Globoside seems to be necessary for B19 attachment,
although its expression level does not correlate with the efficiency of viral binding
(Weigel-Kelley et al., 2001). Weigel-Kelley et al. also showed with a recombinant B19
vector system (Ponnazhagan et al., 1998), that in all cell types expressing globoside on the
plasma membrane, cell-surface binding of B19 occurs but that it is not sufficient for B19
entry (Weigel-Kelley et al., 2001). Expression of marker genes carried by the B19 vector,
indicating viral entry and nuclear transport of the recombinant genome, was seen in two
cell lines of epitheloid origin, 293 and HeLa, and also in two human primary cell lines
(human umbilical vein endothelial cells, HUVEC, and normal human lung fibroblasts,
NHLF), but not in the human erythroleukemia cell lines HEL and K562, despite the
presence of globoside on their surface. Subsequently, B19 entry has been shown to be
mediated by ???1 integrins in high-affinity conformation (Weigel-Kelley et al., 2003) and
regulated in a cell-type specific manner (Weigel-Kelley et al., 2006). Recently, expression
of Ku80 on transfected HeLa cells was shown to enhance the entry of B19, suggesting that
Ku80 mediates efficient B19 entry in cooperation with globoside and probably with ???1
integrins (Munakata et al., 2005).
The presence of globoside has been shown for primary human synovial fibroblasts
(Ray et  al., 2001); however, even high concentrations of the B19 virus could not
productively infect cultured human fibroblast-like synoviocytes (Lu et al., 2006).
However, B19 viremic serum has been reported to induce fibroblast invasiveness (Ray et
al., 2001), to activate synoviocytes and to increase their migration in vitro, apparently by
the phospholipase 2 (PLA2)  activity  of  the  VP1u region  (Lu et al., 2006). The VP1u of
B19 types 2 and 3 differ from the prototype in 11 and 16 amino acids, respectively. Two
of the aa substitutions are located in the PLA2-domains of type 2, and one of type 3, while
several are clustered in the VP1u amino terminal region. Whether these substitutions alter
the PLA2 function of B19 types 2 and 3 and the tissue tropism or pathogenicity remains to
be determined.
In primary hepatocytes and HepG2 cells inoculated with the B19 virus, Poole et al.
detected production of NS1, but not VP transcripts or proteins (Poole et al., 2004). The
absence of VP transcripts demonstrated that the infection in hepatocytes was restricted,
with no production of progeny virions. However, NS1 was produced and translocated into
the nucleus, and induced apoptosis in these cells (Poole et al., 2006).
70
B19 DNA was detectable in skin fibroblasts (but not in keratinocytes) cultured from a
systemic sclerosis patient, and remained so for several in vitro passages (Ferri et al.,
2002). B19 mRNA by in situ RT-PCR has been seen in endothelial cells, in the
surrounding mononuclear cells, and in fibroblasts of skin biopsies from patients with a
spectrum of connective tissue diseases (Magro et al., 2002; Magro et al., 2004).
Zakrzewska et al. claimed low-level B19 infectivity of human dermal fibroblasts and
human umbilical vein endothelial cells, as evidenced by detection of equal levels of NS1-
and VP1- mRNAs (Zakrzewska et  al., 2005). However, RNA transcription is not
necessarily followed by the production of viral proteins and replication (Gallinella et al.,
2000; Pallier et  al., 1997). No direct evidence of active replication was observed
(Zakrzewska et  al., 2005). Taken together, these studies show that the B19 virus might
attach to and be internalized into cells that do not support B19 replication.
Mechanisms of persistence
If not actively replicating, how could viral DNA be maintained in human tissues for
almost a century? The DNA might be integrated into human chromosomes or stored as
episomes, or it could even be encapsidated, eg. stay attached on the surface of follicular
dendritic cells or perhaps carried inside macrophages as full virions, in accordance with
our results suggesting intactness of the persisting DNA molecule.
Another human parvovirus, AAV2, integrates site-specifically, by a non-homologous
recombination mechanism, into chromosome 19, from where it can be released by aid of a
helper virus or other external stimuli (Kotin et al., 1990; Kotin et al., 1991; Kotin et al.,
1992). The ability to integrate site-specifically into synthetic cellular episomes has been
demonstrated also for minute virus of mice (MVM) (Corsini et  al., 1997). Kerr et al.
found several short regions (17-26 nucleotides) of sequence identity between B19 and the
human genome (Kerr and Boschetti, 2006), which could possibly be involved in
promoting the B19 DNA persistence, e.g. through homologous recombination, or
regulatory effects on host transcription, possibly accomplished via mRNA splicing or
RNA interference. However, no clear evidence yet exists for B19 virus chromosomal
integration.
It is not known whether B19 could in certain conditions, such as stress or
immunosuppression, be released from latency. Reports of putative endogenous re-
activations of B19 virus are rare, possibly also in part because they are difficult to identify
– i.e. to be distinguished from dormant persistence and from possible re-infections among
immunocompromized hosts (Muetherig et  al., 2007; Soderlund et al., 1997a). However,
B19 type 2, being rarely seen in primary infection but commonly detected in the tissues,
(III; Heegaard et al., 2001; Norja et  al., 2006), has been encountered in the blood of
HBV/HCV co-infected patients or in immunodeficient subjects conspicuously often
(Table 9).
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The persistence of B19 genomes of virus type 2 can not be attributed to reinfections,
since that virus type is absent from current circulation (III; Heegaard et al., 2001; Norja et
al., 2006). One hypothetical mechanism for the life-long DNA persistence could be
equilibrium between viral replication and efficiency of host immunity. However, an
immunological  difference  is  not  likely  to  explain  the  absence  of  B19  type  2  DNA  in
tissues of the young because of the similarity in B-cell immunity between the three virus
types (IV; Blumel et  al., 2005; Heegaard et al., 2002b; Parsyan et al., 2006)  and the
paucity of viremic type 2 infections during the recent decades. To investigate the role of
the immune system in controlling replication of the persisting viral DNA molecules,
Manning et al. recently examined the levels of B19 DNA in bone marrow, lymphoid
tissue  and brain  collected  from HIV infected  subjects  at  pre-AIDS or  in  terminal  AIDS,
and from HIV uninfected individuals. No positive correlation was observed between
median viral loads and immunosuppression. On the contrary, the loads in the HIV
uninfected individuals were the highest (Manning et al., 2007).
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Table 9: Reported B19 type 2 and 3 cases
Type 2 Strain Sample Year Clinical signs Reference
E99.3 Serum 1999 Rash Servant et al. 2002
E99.4 Serum 1999 Anemia, immunocompromised Servant et al.  2002
A6 Serum 1991 Chronic anemia, HIV Nguyen et al.  2002
IM-81 Plasma ? ?, Plasma donation Blumel et al.  2005
Serum 2001 Anemia, renal transplant recipient Liefeldt et al.   2005
04BR0081 Bone marrow 2004 Renal transplantation, HHV6, pancytopenia Sanabani et al.  2006
Serum (2) 2000-2002 HBV Toan et al.  2006
B19-SJ Serum/plasma 2000 Renal transplant, anemia Cohen et al.  2006
GEStgt1 Serum 1996-2002 Pregnant woman with rythema infectiosum Enders et al.  2006
Factor III concentrates <1980 Schneider et al.  2004
Factor III concentrate <2004 Schneider et al.  2004
Livers (5) ? HBV or HCV Wong et al. 2003
skin birth year ? 1972 B19 non-related II
skin, synovia, tonsils, liver birth year ? 1972 B19 non-related Norja et al. 2006
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Type 3 Strain Sample Year Clinical signs Reference
A95.1 Serum 1995 Chronic anemia, HIV Servant et al.   2002
D91.1 Serum 1991 Aplastic crisis, G6PD defect, minor thalassemia Servant et al.   2002
E99.2 Bone marrow 1999 Pancytopenia, HCV Servant et al.   2002
E00.2 Serum 2000 Pregnant, fever Servant et al.   2002
E01.1 Serum 2001 Aplastic crisis, immunocompetent Servant et al.   2002
03BR0440 Bone marrow 2003 Endometriosis, febrile pancytopenia, hemophagocytic syndrome Sanabani et al.  2006
03BR0570 Bone marrow 2003 Hepatic transplantation, colitis, pancytopenia Sanabani et al.  2006
03BR0057 Bone marrow 2004 Hepatic transplantation, anemia Sanabani et al.  2006
04BR0290 Bone marrow 2004 Hepatic transplantation, diarrhea, pancytopenia Sanabani et al.  2006
04BR0445 Bone marrow 2004 T-cell leukemia, anemia, neutropenia Sanabani et al.  2006
04BR0448 Bone marrow 2004 Diabetes, pancytopenia, hemophagocytic syndrome Sanabani et al.  2006
V9 Serum 1995 microcytic anemia, G6PD defect, Nguyen  et al. 1999
R1 Serum 1998 chronic renal insufficiency, macrocytic anemia Nguyen  et al. 1999
E99.1* Blood 1999 Chronic anemia, HIV Servant et al.   2002
E00.1* Bone marrow 2000 Aplastic crisis, Waldenstrom disease Servant et al.   2002
E00.3* Bone marrow 2000 Chronic anemia, HIV Servant et al.   2002
E00.4* Serum 2000 Anemia, immunocompromised Servant et al.   2002
B19-AQ Serum 2005 Chronic renal failure, anemia, red cell aplasia Cohen et al.    2006
Plasma 2001-2003 blood-donors, Ghana (1.3%) Candotti et al.  2004
Plasma pregnant women, Ghana (1.8%) Candotti et al.  2006
Plasma 2003-2005 blood-donors, Ghana (1.8 %) Parsyan et al.  2006
Liver Liver ? HBV or HCV infection Wong et al.  2003
LiverH41 Liver ? Fulminant hepatitis, HCV not tested Wong et al.  2003
74
Concluding remarks
This  thesis  describes  the  discovery  and  characteristics  of  a  new  B19  variant,  LaLi,  a
representative of B19 genotype 2. As is known for the B19 prototype, DNA of this new
virus type was shown to persist in solid tissues of nonsymptomatic humans with
serological evidence of pre-existing immunity. Comparison of the viral genomes from
synovial tissues of subjects with acute-phase infection and long-term immunity suggested
that the viral DNAs persist apparently as intact molecules without persistence-specific
mutations.  Interestingly, type 2 viremias were not found among blood-donors, strongly
suggesting that (in Europe) B19 type 2 is absent from wide circulation.
Even though type 2 and 3 viremias are rare,  and in most  studies only their  DNA has
been detected, our work concerning the biological and immunological relations of the new
B19 types show that they indeed are biologically active viruses, with the capacity for
mRNA production and expression of both non-structural and structural proteins leading to
formation of infectious virions. In concordance with recent studies showing similar
kinetics for mRNA expression of types 1 and 2 in cell culture (Blumel et al., 2005), our
results showed similar transcription efficiency for the p6 promoters of all three virus types.
Furthermore, the comparison of p6 activity in various cell types suggested similar tropism.
However, their striking difference in temporal occurrence and geographical distribution
(Norja et al., 2006) still awaits explanation. The cessation of B19 type 2 from circulation
might be a fitness-related phenomenon resembling the replacement of CPV2 by the more
effective lineage CPV2a (Parrish et  al., 1988; Shackelton et al., 2005).  Additional
investigations, including measurement of the phospholipase A2 activity (Dorsch et al.,
2002; Lu et al., 2006; Zadori et al., 2001), definition of the additional functions of NS1,
and elucidation of the impact of the 7.5 and 11 kDa proteins (Zhi et  al., 2006) and the
polyadenylation regulation sites (Yoto et  al., 2006), may be needed to identify the
molecular background of the epidemiological difference between the three B19 virus
types. However, our studies on their molecular biology show that the three B19 genotypes
are, despite their sequence and epidemiological differences, highly similar variants of the
same species. Furthermore, immunological studies by us and others suggest that the three
B19 types would constitute a single serotype.
Life-long persistence of B19 genomic DNA in human solid tissues is the normal
outcome of B19 infection, complicating the interpretation of positive B19 DNA findings
in human tissue. Thus far, the persistence in healthy individuals has been shown for B19
types 1 and 2. Further studies are needed to investigate the molecular and cellular
mechanisms, as well as the biological activity and possible pathogenetic potential of the
B19 genome persistence.
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The  tissue / cell types harbouring the persistent B19 DNA, the molecular and cellular
mechanisms by which the persistence is maintained, as well as the biological activity and
possible pathogenetic potential of the persistent B19 genomes needs to be elucidated.
Additional studies are also needed to determine whether the persistence mechanism is
shared among all the known B19 types (including type 3), and among the newly found
species of human parvoviruses, human bocavirus (HBoV) (Allander et al., 2005) and
PARV4 (Fryer et al., 2006; Jones et al., 2005). Such information will help in development
of new methods (e.g. based on quantification of viral loads, mRNA or antigen detection,
and serology) for the diagnosis of acute and chronic B19 infections.
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